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Abstract 
 
       Dendritic cells (DCs) are professional antigen-presenting cells that are integral to the 
induction of primary, antigen-specific T cell responses. In the cancer setting, DCs mediate cross-
priming of tumor-reactive T cells by presenting tumor antigens acquired from viable or dead 
cancer cells. Due to their unique functional properties, DCs have been utilized as both vectors 
and targets for immunological intervention in numerous diseases and are optimal candidates for 
vaccination protocols in cancer. In addition to their antigen presentation function(s), recent 
evidence suggests that DCs may also perform an innate immune effector function, with human 
DCs reported to mediate direct tumoricidal activity in vitro. However, the mechanism(s) by 
which DCs directly kill tumor cells remain unclear. The goal of this study is to further 
characterize the mechanism(s) associated with murine DC tumoricidal function and to determine 
whether and how this function may be enhanced to promote anti-tumor immune responses that 
translate into therapeutic effectiveness. 
One way we sought to enhance this DC effector function was through the genetic 
engineering of DCs themselves. After transduction with mIL-12 and/or mIL-18 cDNA using 
recombinant adenoviral vectors, DCs exhibited significantly elevated tumor killing activity. This 
was mediated, at least in part, by TNF ligand-receptor complexes, as demonstrated by antibody 
blocking assays. When injected in situ, these engineered DCs exhibited prolonged survival, in 
 iii
association with enhanced levels of tumor apoptosis proximal to imaged DCs and our capacity to 
image DC that had engulfed tumor apoptotic bodies. We also observed notable therapeutic 
benefits upon intratumoral delivery of these DCs in concert with an expanded in vivo repertoire 
of anti-tumor CD8+ T cells. In addition to DC modification, we also evaluated treatments 
applied to tumor cells that resulted in enhanced sensitivity to (control) DC-mediated killing.  
Specifically, we found that pretreatment of A20 lymphoma cells with a nitric oxide (NO) donor 
compound, PAPA-NO, markedly increased the sensitivity of tumor cells to consequent apoptosis 
mediated by DCs.  This appeared to provide DCs with a preferred source of tumor antigens, with 
which, they were capable of activating specific T cells via a cross-presentation pathway.  We 
have also discovered that multiple TNF family ligands participated in DC-mediated tumoricidal 
function and that tumor cell-expressed survivin may represent a critical downstream factor 
regulating the apoptotic sensitivity of tumor cells to DC-mediated apoptosis. When taken 
together, these studies provide novel details regarding mechanisms involved in DC anti-tumor 
effector function, and suggest two DC-based, combinational cancer therapies that target the 
effective cross-priming of therapeutic T cells.  The results presented in this dissertation support 
an efficient model in which DCs may not only serve as the gatherers and presenters of antigens, 
but also the hunters as well, with tumoricidal activity mediated via TNF family ligands.  
 iv
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1. INTRODUCTION 
 
1.1. Cellular immunity in cancer 
The cancer immunosurveillance hypothesis was proposed some decades ago (1, 2). Since 
then, the question of whether the immune system can prevent and/or regulate tumor growth has 
been commonly asked. Recent reports have suggested that mice lacking specific cellular 
populations, such as T cells, natural killer (NK) cells and/or natural killer T (NKT) cells, or 
specific effector molecules, such as interferon (IFN)-γ, interleukin (IL)-12, perforin, or tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) display a higher incidence of tumor 
development (3-7). This provides strong evidence that effective cancer immunosurveillance 
exists in mice. Importantly, accumulating evidence also indicates that the immune system is also 
actively invoked in human anti-cancer defence, for instance: (a) immunosuppressed transplant 
recipients display higher incidences of various non-viral tumors (8); (b) the presence of 
lymphocytes within the tumor can be a positive prognostic indicator of patient survival (9); and 
(c) cancer patients are able to develop spontaneous innate and acquired immune responses to the 
tumors that they bear (10). The discovery that host lymphocytes can indeed recognize and 
destroy tumor cells provides researchers with the opportunity to intensively test a broad array of 
immunotherapies in pre-clinical models and clinical trials (7). At the present time, however, we 
continue to gain an appreciation of the profound immune deviation that occurs both systemically 
and locoregionally within the tumor microenvironment of patients with cancer (11), providing 
additional levels of complexity to model development, therapy design and data interpretation.   
          Protective immune responses can be largely segregated into cellular and humoral immunity, 
that appear to be predicated on two dominant types of cytokines produced early during cognate 
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 dendritic cell (DC)-T cell interaction. Type-1 cytokines (i.e. IL-2, IL-12, and IFN-γ) are involved 
in T helper 1 (Th1) immune responses and notably promote cell-mediated inflammatory 
immunity, which has been typically linked with a better clinical prognosis in the cancer setting 
(12). Two critical effector functions associated with the eradication of developing tumors are the 
production of IFN-γ and cytotoxicity mediated by Type-1 effector (mainly T, NK) cells. In 
contrast, Type-2 cytokines (i.e. IL-4, IL-5, and IL-10) are strong promoters of humoral 
(antibodies) responses to tumor antigens, that are generally poor regulators of progressive tumor 
growth (13, 14).  
Among immune cells, DCs play a crucial instructive role early in adaptive immune 
responses. DCs producing IL-12p70 (i.e. DC1) prime Type-1 (cellular) immune responses, 
whereas DCs that fail to produce IL-12p70 (i.e. DC2) favor Type-2 (humoral) immunity. In the 
cancer setting, IL-12p70 produced by DCs appears to represent a particularly critical cytokine, as 
it promotes the activation, differentiation and functional polarization of NK, NKT, Th1, and Tc1 
cells, that are integrally involved in the development and maintenance of effective Type-1 anti-
tumor immunity (15, 16).  
 
1.2. Immunobiology of dendritic cells (DCs) 
DCs are bone marrow-derived antigen presenting cells (APCs) that exhibit a unique ability 
to induce primary immune responses, thus permitting the establishment of immunological 
memory (17-19). Circulating progenitor DCs enter tissues, where they differentiate to and reside 
as immature DCs (iDC). During tissue damage, iDC capture antigens and migrate to the tissue-
draining lymphoid organs, during which time they mature, and consequently activate rare 
antigen-specific T cells, and thereby initiate immune responses. DCs present antigen to CD4+ T 
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 helper cells (and to CD8+ T cells), which in turn, secrete cytokines and regulate the development 
and function of immune effectors, including antigen-specific CD8+ cytotoxic T cells and B cells, 
as well as non-antigen specific macrophages, eosinophils and NK cells (18, 20).   
 
1.2.1. DC antigen capture, processing and presentation 
In most tissues, DCs exist in an “immature” state, characterized by an optimized ability to 
capture exogenous antigens in their microenvironment (17). Given their expression of a wide 
array of cell-surface receptors, iDCs can efficiently capture bacteria, viruses, apoptotic and 
necrotic cell fragments, proteins and immune complexes through several pathways: such as (a) 
macropinocytosis; (b) receptor-mediated endocytosis via C-type lectin receptors, such as the 
macrophage mannose receptor and DEC-205, which bind to bacterial carbohydrates (21, 22); and 
via FcγRII (CD32), FcγRI (CD64), FcεRI and the C3bi complement receptors (CD11b), which 
increase the efficiency of immune complex endocytosis (23, 24); (c) phagocytosis of particles 
such as latex beads, apoptotic and necrotic fragments (involving CD36 and αvβ3 or αvβ5 
integrins) (25-27); and (d) internalization of heat-shock protein gp96 and hsp70 via toll-like 
receptor 2/4 or CD9 (28-30). 
Captured antigens are processed into peptides that may be loaded into Major 
Histocompatibility Complex (MHC) class I and II molecules. These peptide-MHC complexes are 
consequently transported to the cell surface, allowing for recognition by antigen-specific CD8+ 
and CD4+ T cells, respectively (18). Endogenously synthesized proteins of either self- or 
pathogen-origin typically enter the cytosolic pathway in which proteins are degraded into 
peptides by the (immuno)proteasome and then transported by the transporters of antigen-
processing (TAP) molecules into the endoplasmic reticulum for loading into nascent MHC class 
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 I molecules. In contrast, exogenously acquired proteins are generally degraded in 
endosomes/lysosomes, where the peptides are loaded onto MHC class II molecules following 
degradation of the MHC II-associated invariant chain in the MIIC/endosomal/lysosomal 
compartments of the cell (31-33). 
Besides these two typical antigen-processing pathways, an exogenous pathway for 
processing MHC class I-restricted antigens within DCs has also been reported (Figure 2). Bevan 
et al. (34) showed some years ago that protein antigens synthesized in one cell could be captured 
as exogenous antigens by APCs, processed into the MHC class I-presentation pathway, and then 
used to prime CTL-mediated immunity. This was termed “cross-priming”. Subsequently, the 
antigen-processing associated with cross-priming was defined as “cross-presentation” (34, 35). 
Cross-presentation has been previously used in two contexts in the literature. In the first case, it 
simply refers to the processing of exogenous antigens into the MHC class I pathway. The second 
definition allows for the capture and re-presentation of cell-associated antigen in either the MHC 
class I or MHC class II pathways (32). Cross-presentation as described in this thesis refers to the 
latter definition.   
 
1.2.2 DC maturation 
Maturation is a terminal differentiation process that transforms DCs from cells specialized 
in antigen capture into cells specialized for T cell stimulation (36). DC maturation can be 
induced following interaction with diverse stimuli. Bacterial products such as lipopolysaccharide 
(LPS) or uptake of apoptotic bodies can induce DC maturation. Signals also act on receptors that 
trigger intracellular signaling, including receptors for host-derived inflammatory molecules such 
as CD40 ligand (CD40L), tumor necrosis factor α (TNFα), IL-1, and IFNα (31). 
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 Upon maturation, the expression pattern of many DC surface markers and secreted factors 
changes dramatically. Mature DCs (mDC) lose some of their antigen processing capacity and, 
instead, acquire numerous appendages/processes (dendrites), allowing mDCs to increase their 
motility and migrate toward the regional lymph nodes (LN) (17). MDCs also increase their level 
of membrane-localized MHC class II complexes and exhibit significantly higher levels of 
accessory/costimulatory molecule expression than iDCs, including CD40, CD80, CD83 and 
CD86. Furthermore, they also display a distinct cytokine and growth factor profile, perhaps best 
characterized by their ability to produce increased levels of IL-12p70 in response to 
environmental stimuli (24, 37). 
 
1.2.3. DC Interaction with lymphocytes 
One of the primary events after maturation is the programmed up-regulation in expression 
of the chemokine receptor CCR7 on the DC surface, providing DCs the capacity to respond to 
the secondary LN chemokines ELC/MIPβ and SLC/6Ckine (38). These ligands are 
chemoattractants for DCs and are specifically expressed in the T-cell-rich areas of LNs, where 
mature DC home to and become interdigitating DC (39). 
Initial DC-T cell interactions are mediated, in part, via adhesion molecules, such as DC-
SIGN/ICAM-3, ICAM-1/LFA-1 and LFA-3/CD2 (36, 40). Following recognition of MHC-
peptide complexes on DCs by antigen-specific TCRs (signal 1) and engagement of T cell 
expressed CD28 molecules by DC expressed B7-1 and B7-2 co-stimulatory molecules (signal 2), 
DCs become competent to stimulate the activation, expansion and differentiation of T 
effector/memory cells.  Naïve CD8+ T cells can be primed directly by DCs, even in the absence 
of T cell help (41, 42). In the case of CD4+ T helper cells, activation (by DC) in the presence of 
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 IL-12p70 promotes the functional development of IFNγ-producing Th1-type T cells that, in turn, 
support the differentiation and maintenance of CD8+ cytotoxic T lymphocytes (CTLs).  When 
activated by DCs in the presence of IL-4, however, T cells differentiate into Th2-type effector T 
cells that secrete IL-4, IL-5 and IL-13. These cytokines activate eosinophils, and serve as B cell 
growth and differentiation factors, favoring the development of humoral immunity (15, 17).  
 
1.2.4 DC tumoricidal function 
In addition to their capacity to mediate antigen presentation, several recent reports suggest 
that DCs may also directly ‘kill’ target cells. Initial results published in 1996 suggested that 
CD8+ DCs express FasL and are well equipped to kill activated, Fas-expressing CD4+ T cells 
(43). These data indicated that DCs expressing FasL could be functionally specialized to mediate 
the apoptotic death of Fas+ target cells. Accordingly, it was recently reported that DCs also 
exhibit direct cytotoxic activity against a wide range of tumor cell lines in vitro.  After 
stimulation with either IFN-α or IFN-γ, human CD11c+ blood DCs acquire the ability to kill 
tumor cell targets (44). Human CD34+ stem cell-derived DCs and human CD14+ monocyte-
derived DCs, stimulated with IFNβ, also exhibit cytotolytic reactivity against certain types of 
tumor cells (45). Such tumoricidal activity appears to be principally mediated by DC-expressed 
TRAIL molecules. Others have argued that human DCs induce tumor-specific apoptosis via a 
Fas/FasL-dependent pathway (46), or by secretion of soluble factors (47).  In rat, a subset of DCs 
exhibit cytotoxic activity against selected tumor cells, via both Ca2+- dependent, and -
independent mechanisms (48).  Moreover, our group has recently reported that human monocyte 
derived and fresh blood iDCs directly and effectively induce apoptosis via caspase 8 and caspase 
9 pathways in a large variety of cultured and fresh cancer cells, without damaging normal cells, 
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 and that blocking antibodies specific to TNF family ligands, TNF, FasL, LT-α1β2, and TRAIL, 
inhibit the killing of cancer cells by DCs (49, 50).  Despite these findings, even now, the detailed 
mechanism(s) by which DCs kill cancer cells remains incompletely understood.  
 
1.3. Apoptosis 
Apoptosis, or programmed cell death, is an essential physiological process that plays a 
critical role in embryonic development, immune system function and the maintenance of tissue 
homeostasis (51). However, apoptosis is also involved in a wide range of pathological 
conditions, including cancer. Defects in the apoptosis pathways can eventually lead to expansion 
of a population of neoplastic cells. Resistance to apoptosis can also augment the escape of tumor 
cells from surveillance by the immune system. The goal of cancer therapy is to selectively 
promote the death of cancer cells without causing unacceptable levels of collateral damage to 
normal cells/tissues (52-54). 
 
1.3.1. Apoptosis pathways 
Upon initiation of apoptosis, cells may undergo specific morphological and biochemical 
changes, including cell shrinkage, chromatin condensation, and internucleosomal cleavage of 
genomic DNA (51). At the molecular level, apoptosis is mainly orchestrated by the activation of 
the aspartate-specific cysteine protease (caspase) cascade. To keep the apoptotic program under 
control, caspases are initially synthesized as inactive precursor proteins (zymogens) that are 
cleaved by an upstream protease, or by an increase in the local concentration that leads to 
cleavage-independent activation, to produce a mature protein with full enzymatic activity (55).  
7 
 In principle, there are two pathways that initiate apoptosis: one is the “extrinsic pathway” 
mediated by death receptors on the cell surface; the other is the “intrinsic pathway” involving 
mitochondria (54). In a simplified description of the extrinsic pathway, binding of ligands such 
as FasL, TNF, or TRAIL to their corresponding receptors (i.e. Fas, TNF receptor or TRAIL 
receptor, respectively) results in the formation of the death induced signaling complex (DISC). 
The DISC contains the adaptor proteins that allow for the recruitment of pro-caspase-8, which 
leads to its autoactivation. Active caspase-8, often referred to as an initiator caspase, 
subsequently cleaves and activates pro-caspase-3. Activation of caspase-3, the effector caspase, 
leads to the ultimate demise of the cell (54-57).   
Alternatively, the intrinsic pathway is triggered by various extracellular and intracellular 
stresses, such as growth factor withdrawal, hypoxia and DNA damage. These stresses induce a 
series of biochemical events that result in the translocation of a pro-apoptotic Bcl-2 family 
member, such as Bax, into the mitochondria, and the release of cytochrome c from mitochondria 
into the cytosol. This may be accompanied by loss of mitochondrial membrane potential and 
destabilization of the outer mitochondrial membrane. In the cytosol, cytochrome c forms a 
complex with apoptotic protease activating factor 1 (APAF1), ATP and inactive initiator caspase 
pro-caspase-9. Within this complex  known as the “apoptosome”  caspase-9 is activated, 
which allows for the consequent activation of caspase-3, eventually resulting in apoptosis (55-
57).  
Despite these simplified schemes, there is undoubtedly crosstalk between these two 
pathways. For example, cleavage of the Bcl-2 family member bid by caspase-8 induces 
translocation of bid to the mitochondria and triggers the intrinsic apoptotic pathway. This is 
proposed to serve as a potentiating loop to amplify the apoptotic signal (58). 
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1.3.2. Regulators of apoptosis 
The apoptotic self-destruction machinery is tightly-controlled, with various proteins 
regulating the apoptotic process at different levels. FLIPs (FADD-like interleukin-1 β-converting 
enzyme-like protease (FLICE/caspase-8)-inhibitory proteins) interfere with the initiation of 
apoptosis directly at the level of death receptor (57). In addition, two other major families of 
apoptosis regulators have been identified to date: the Bcl-2 family and the inhibitor of apoptosis 
proteins (IAP) (59). 
The members of the Bcl-2 family are an important class of proteins that regulate apoptosis 
at the mitochondrial level. According to their function, these proteins can be divided into anti-
apoptotic (Bcl-2, Bcl-xL, Bcl-w, Mcl-1) and pro-apoptotic proteins (Bax, Bak, Bid, Bad). Most 
anti-apoptotic members contain the Bcl-2 homology (BH) domain 1, 2 and 4, whereas the BH3 
domain seems to be crucial for apoptosis induction (57). Once activated, the pro-apoptotic 
proteins, Bax and Bak, are able to perturb the membrane permeability of mitochondria where 
they localize. This results in the release of apoptogenic proteins, such as cytochrome c, from the 
mitochondria into the cytosol (60). These effects are counterbalanced by the anti-apoptotic 
activity of survival members, such as Bcl-2, Bcl-xL, and the ratio between anti-apoptotic and 
pro-apoptotic proteins helps to determine overall cellular susceptibility to death stimulations (60, 
61). The protective function of Bcl-2 and Bcl-xL appears to be mediated by formation of 
inactivating heterodimers with Bax/Bak, thus preventing the release of apoptogenic factors that 
would otherwise occur in response to apoptotic stimuli (62).  
In addition to proteins such as Bcl-2 that inhibit cell death upstream of the mitochondria, 
and prior to activation of the caspases, there is another family of proteins termed IAPs that act 
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 after caspases become activated by binding to them and preventing them from cleaving their 
substrates (63). They might also function as ubiquitin ligases, promoting the degradation of 
bound caspases (57). Eight human IAP family members, also known as baculovirus IAP repeat-
containing (BIRC) proteins, have been identified thus far, these include: c-IAP1, c-IAP2, XIAP, 
NIAP, survivin, apollon, ML-IAP and ILP2 (64). 
Being a novel member of the IAP family, survivin has recently attracted attention from 
both basic and translational researchers. At 16.5kDa, survivin is the smallest member in the 
mammalian IAP family (65). A number of distinct features enable this protein to become an 
attractive candidate target in cancer therapy design. Survivin is ubiquitously expressed during 
embryonic and fetal development, but is undetectable in most normal adult tissues. In contrast, 
dramatic overexpression has been shown for virtually all cancers thus far evaluated, including 
carcinomas of the lung, colon, breast, pancreas, stomach, liver, ovaries, as well as, 
haematopoietic malignancies (65, 66). Several lines of evidence also suggest that survivin is a 
reliable marker of aggressive and unfavorable disease, and is associated with an abbreviated 
overall survival of cancer patients (66-68). When taken together, these features indicate that 
survivin may serve as a ubiquitously-expressed tumor-associated antigen for both diagnostic and 
therapeutic purposes (65). 
Another unique property of the survivin protein is its duality of function.  One question that 
has frequently been asked is whether survivin is predominantly an apoptosis inhibitor, a mitotic 
regulator, or whether it equally participates in both processes (66). Despite controversy in the 
reports published, a role for survivin in apoptosis inhibition is now well-established. In cell 
culture systems, overexpression of survivin inhibits apoptosis initiated via the extrinsic or 
intrinsic apoptotic pathways (65). Molecular antagonists of survivin cause caspase-dependent 
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 cell death and lead to an enhancement of sensitivity to apoptotic stimuli (69, 70). Although not 
conclusively determined, the mechanism by which survivin exerts its inhibitory function(s) on 
apoptosis circuitry appears to be through its interaction and inhibition of caspases -3, -7, or -9 
(65, 71). In addition to its involvement in cell death regulation, survivin also appears to play an 
important role in cellular mitosis. The kinetics of survivin expression display a clear cell-cycle 
dependency (72). During mitosis, survivin localizes to various components of the mitotic 
apparatus, such as centrosomes, microtubules of the metaphase and anaphase spindle, and the 
remnants of the mitotic apparatus  midbodies (66). Intriguingly, a very recent report showed 
that survivin is required for both proliferation and inhibition of apoptosis of expanding T cells 
and that these two processes are so inter-dependent that they cannot be functionally- or 
temporally-dissociated from one another (73, 74).   
 
1.3.3. TNF family ligands and their receptors 
TNF ligand superfamily members induce pleiotropic biological responses, including cell 
activation, proliferation, differentiation, and death (75). The ability to induce cell death is a 
unique feature of the TNF ligand family and has been well established for TNF-α, FasL and 
TRAIL (75, 76). TNF-α, FasL and TRAIL are synthesized as type II transmembrane proteins that 
contain a short cytoplasmic segment and a relatively long homotrimeric extracellular region, 
which are not only expressed as membrane-bound molecules, but also secreted as soluble 
proteins after proteolytic cleavage (77).  
In parallel with the elucidation of the TNF ligand superfamily, a large family of 
complementary molecules, named the TNF receptor superfamily, has also been identified.  All 
members of this family are type I membrane-bound proteins containing characteristic cysteine-
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 rich repeats in their extracellular domains (77).  Functional TNF receptors usually exist as 
trimeric complexes that are stabilized by intra-cysteine disulfide bonds.  Although sequence 
homology in the cytoplasmic domains does not exceed 25%, the death domain is shared by the 
apoptosis-inducing receptors TNF receptor 1 (TNFR1), Fas, death receptor 3 (DR3), DR4 and 
DR5 (77-80).  
TNF family ligand/receptor complexes play important roles in both innate and adaptive 
immune responses. TNF-α and FasL are expressed on activated CTLs and NK cells, and exhibit 
potent cytotoxic activity, inducing apoptosis in susceptible cells within hours (77, 81-83).  
Numerous lines of evidence have shown a pivotal role of FasL in regulating normal B and T cell 
function, suppression of autoimmunity, control of infection, and immune surveillance (84-87). In 
particular, expression of FasL on DCs appears to be involved in maintaining lymphocyte 
homeostasis (88, 89).  Among the known apoptosis-inducing molecules, TRAIL has received a 
significant degree of attention in the past few years.  One of TRAIL’s unique characteristics is 
the induction of apoptotic cell death of a variety of tumor cells or transformed cells, but not 
normal cells (90).  TRAIL is expressed on the surface of activated T lymphocytes, NK cells and 
monocytes, and has been shown to participate in tumoricidal activity in vitro and in vivo (91-94). 
 
1.4. Cancer immunotherapy 
When cells become cancerous, they may produce new, uncommon antigens. The immune 
system may recognize these antigens as “non-self” and destroy cancer cells expressing the 
antigens. However, it has been well-characterized that immune function is frequently impaired in 
cancer patients, and that tumor cells may evolve a variety of mechanisms in order to circumvent 
anti-tumor immune responses (95). Tumor escape strategies include the: (a) absence or down-
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 modulation of MHC molecule expression on tumor cells; (b) reduced or deficient expression of 
co-stimulatory molecules and adhesion molecules on cancer cells; (c) production of 
immunosuppressive soluble factors (e.g. IL-10, TGF-β); (d) expression of FasL and/or absence 
of Fas receptor (95-97). In addition, the failure of host defense mechanisms (i.e. impaired T, NK, 
or APC cell function) may also be related to the ability of tumor cells to progress(95, 98). 
It is now known that tumor cells may be eliminated by the immune system through both 
cellular and humoral responses.  Cellular cytotoxicity is believed to play a critical role in anti-
cancer immunity (95, 99). Cancer immunotherapy is an approach to the treatment of cancer, 
which is designed to induce or up-regulate T cell-mediated tumor-specific immune responses 
(100). In this regard, numerous strategies have been developed, which include non-specific 
activation of the immune system with microbial components or cytokines, antigen-specific 
immunotherapy with passive transfer of antibodies and/or T cells, and antigen-specific active 
immunotherapy (i.e. vaccination) (37). Among these modalities, the most attractive strategy may 
be vaccination, which is expected to induce both therapeutic T-cell immunity (by stimulating 
tumor-specific effector T cells) and protective T-cell immunity (by stimulating tumor-specific 
memory T cells that can prevent patient relapse) (37, 101). 
 
1.4.1. DC-based cancer therapy 
Many recent vaccine designs have targeted the optimization of antigen delivery to DC in 
situ, due to the unique immunostimulatory properties of these APCs, including their high degree 
of antigen capture and presenting capacities that support the extremely efficient induction and 
maintenance of specific cell-mediated immune responses (31, 102). Recently, a novel approach 
to vaccination against cancer was reported, which exploited DCs and their “natural adjuvant” 
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 qualities, by actively immunizing cancer patients with a sample of their own DCs that had been 
pulsed ex vivo with tumor antigens (103). The rationale for using DCs as a component of an anti-
tumor vaccine is compelling: DCs are not only capable of internalizing and processing tumor 
epitopes, of migrating to regional LNs and optimally-presenting these epitopes to T cells, but 
also of secreting cytokines that promote the amplification of T-cell responses and the 
development of immunologic memory (36, 37). The recent discovery that DCs are functionally 
compromised in patients with cancer provides another reason for the use of ex vivo generated 
DCs in cancer vaccines, where their function and numbers may be selected and regulated (104). 
Moreover, ex vivo differentiated autologous DCs obtained either from peripheral blood 
monocytes or bone marrow stores of patients with cancer appear fully-functional, and may be 
readily used in vaccines (24). 
The choice of tumor antigen to be employed in DC-based vaccines is an important 
consideration. MHC class I-restricted peptide antigens are frequently used, including altered or 
enhanced peptides (i.e., altered/agonist peptide ligands; APL) that boost immunity to less 
immunogenic self-antigens or that improve antigen presentation or T-cell receptor affinity (31, 
105). Pulsing synthetic peptides derived from known tumor-antigens such as MAGE-1, MART-
1, gp100 or MUC1 onto human DCs has been shown to represent an effective therapeutic 
vaccine in the clinical setting (106-109). The disadvantages of using defined tumor antigens are 
that loaded peptides only reside on the DC surface (in the context of specific MHC allelic 
proteins) for a short period of time and most antigenic peptides are only applicable for patients 
who express a defined, specific Human Leukocyte Antigen (HLA) type that is capable of 
presenting a given epitope to T cells (36, 110). In response to these vaccines that serve a sub-
population of patients, DC/whole protein-based strategies that do not require prior knowledge of 
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 the patient’s MHC haplotype have been developed. DCs can be loaded with purified or 
recombinant proteins, transduced with non-replicating recombinant viral vectors, or transfected 
with RNA encoding tumor-associated antigens (31, 36).  Each of these approaches allows the 
host’s MHC molecules to select epitopes from the target antigen’s complete amino acid 
sequence.  
The route of DC administration can clearly affect the consequent tissue localization of the 
injected cells and their “immunogenicity”; and therefore, this variable has been intensively 
investigated. Typically, “therapeutic” DCs are administered either intradermally, intravenously, 
or, in special circumstances, intraperitoneally (24). However, most clinical protocols require very 
high numbers of DCs for vaccination, since only a very small amount of the injected DCs 
actually reach the tissue-draining LNs, as has been demonstrated in animal models (111). The 
delivery of DCs directly into tumors represents an attractive alternative approach in stimulating 
improved anti-tumor T cells responses in situ, via cross-priming. This is additionally supported 
by reports that have demonstrated that human DCs mediate tumoricidal activity against cancer 
cells via TNF-ligand/TNF-receptor interactions, which might lead to subsequent uptake and 
cross-presentation of dying tumor cell-associated epitopes in situ (44, 45, 50). A clinical trial for 
patients with colon, pancreatic, and primary liver carcinomas based on ultrasound-guided 
intratumoral injection of DCs expressing recombinant IL-12 is currently ongoing (112). 
 
1.4.2. Cytokine as immune response modifiers 
Cytokines are (glyco)proteins secreted by immune cells as soluble immune messengers  
(113). A diverse array of cytokines are currently being evaluated in cancer therapies designed to 
enhance specific immunity, including:  TNF, IL-4, IL-6 and granulocyte/macrophage colony-
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 stimulating factor (GM-CSF), among others.  Of some concern, where evaluated, these agents 
have been found to be either ineffective or to provide controversial results (100, 113). Other 
major cytokines that are currently the focus of intense research include: IL-2, IFN-α, and IL-
12p70, which have demonstrated repeated clinical efficacy in the treatment of haematologic 
malignancies or immunogenic solid cancers. 
IL-2 is a T cell growth factor and an activator of T cells and NK cells. In 1992, high-dose 
(HD) bolus interleukin-2 (IL-2) received US Food and Drug Administration (FDA) approval for 
metastatic renal cell carcinoma, based on data that revealed durable responses in a small 
percentage of patients. However, this regimen is associated with significant toxicity and cost, 
which has limited its application to highly-selected patients treated at specialized centers (114). 
Several investigators have evaluated regimens with lower doses of IL-2 in an attempt to decrease 
toxicity. These regimens were reported to produce response rates and survival comparable to HD 
IL-2 with much less toxicity, but possibly fewer durable responses noted (114, 115).  
Interferon (IFN) was first isolated in 1957 and called IFN because it “interfered” with viral 
infection. The role of IFN in cancer was later well-documented and was indicated for the 
treatment of multiple malignancies, including leukemia, renal cell carcinoma, and melanoma 
(116, 117). Currently, IFN-α2b is approved by the FDA for the treatment of cancer and the 
application in clinical trials showed reproducible efficacy. While the toxicity of high-dose IFN-α 
is high, the majority of patients complete treatment with dose modification and nearly all toxicity 
is rapidly reversible (118). 
IL-12 (i.e IL-12p70) is a very exciting cytokine. It has strong inflammatory properties that 
mediate the activation and attraction of innate immune cells, resulting in the recruitment of 
specific immune cells (such as T cells). IL-12 also enhances the maturation and antigen 
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 presention capacity of DCs and promotes T helper cell differentiation towards the Th1-type 
necessary for cellular anti-tumor immune responses. Moreover, it stimulates the differentiation 
and lytic capacity of antigen-specific cytotoxic T lymphocytes (CTL) and promotes immune 
memory (119-121). Recombinant human IL-12p70 has been studied in patients with various 
types of cancer. Although the clinical development of recombinant IL-12 (rIL-12) as a single 
agent for systemic cancer therapy has been hindered by its significant systemic toxicities and 
disappointing anti-tumor effectiveness as a single modality (122, 123), IL-12 remains a very 
promising immunotherapeutic agent, because recent cancer vaccination studies in animal models 
and humans have demonstrated its powerful adjuvant properties (124-126).  
In the immune system, cytokines function in regimented cascades. This may explain in 
part, why clinical trials of individual cytokines are rarely successful, since they tend not to work 
individually, but rather, cooperatively (100).  IL-18 (also known as interferon-γ inducing factor; 
IGIF) is a proinflammatory cytokine that belongs to the IL-1 family. It works synergistically 
with IL-12p70 to enhance IFNγ production by Th1/Tc1 cells (127, 128).  Therefore, combined 
application of both cytokines may further improve the therapeutic effectiveness of these drugs, as 
well as reduce the dose of individual cytokines required clinically.  
 
1.4.3. Genetically-modified recombinant tumor vaccine 
In general, first-generation cancer vaccines were composed of whole cancer cells or tumor-
cell lysates mixed with non-specific adjuvants (24), while second-generation employed 
genetically-modified tumor cells, antigen presenting cells (DCs) or recombinant tumor antigens 
in the absence or presence of adjuvants (95). In particular, a large number of cellular gene-
modified vaccines have been developed, most of which have involved the transfection of cancer 
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 cells or APCs with genes encoding specific tumor antigens, co-stimulatory molecules, HLA 
proteins, as well as cytokines (95), prior to delivery of these modified cell products into patients.  
Gene delivery systems, which form the technological basis for genetically-modified tumor 
vaccines may be divided into two major groups: nonviral and viral (95). Adenoviral vectors are a 
commonly used viral gene delivery system. There are a number of reasons that make them 
preferred for gene delivery when compared to other vectors. Most adenoviruses cause mild 
diseases in immunocompetent human adults and by deletion of crucial regions (i.e. E1, E3 genes) 
of the viral genome the vectors can be rendered replication-defective, which increases the safety 
of these agents. Adenoviruses exhibit a broad target cell tropism, infecting a variety of dividing 
and non-dividing cell types. They can be grown to high titers in tissue culture. They can be 
applied systemically as well as across mucosal surfaces and their relative thermostability profile 
facilitates and expands their clinical utility (129).   
 
1.4.4. Combinational therapies 
Just as cancer chemotherapy began with the use of a single agent and has evolved into 
combination therapy, immunotherapeutic agents have been combined with each other and/or 
with drugs that exert anti-cancer effects. To enhance the anti-tumor immunity elicited by DC-
based vaccination, systemic administration of Th1-biased cytokines, such as IL-2 and IL-12 have 
been applied, resulting in improved therapeutic efficacy (130, 131).  Alternatively, the 
administration of cytokine gene-engineered DCs has been demonstrated to enhance the 
magnitude and diversity of tumor antigen-specific CTL reactivity (132, 133). Furthermore, the 
efficacy of a vaccine designed to promote specific CTLs may be improved by treatment of tumor 
lesions with agents that sensitize target tumor cells to CTL-mediated apoptosis (134-136). 
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 Hence, a combination of sensitization approaches with a more conventional therapy or vaccine 
may yield enhanced therapeutic effectiveness.  
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 Scope of this thesis 
 
Several lines of evidence have recently suggested that, in addition to their professional 
antigen presentation function, DCs may also directly mediate the apoptotic death of tumor cells. 
Attempts to define the means to either enhance DC tumoricidal function or increase the 
sensitivity of tumor cells to this activity would be expected to result in the formulation of novel 
DC-based cancer vaccines and therapies. 
In the first phase of the study, we transduced bone marrow-derived DCs with mIL-12 
and/or mIL-18 and tested whether this modification would enhance DC-mediated cytotoxicity 
against tumor cells, as well as, induce therapeutic immunity. Our data clearly showed that mIL-
12 and/or mIL-18 gene-engineered DCs exhibited elevated tumoricidal activity in vitro. This was 
also confirmed by in situ confocal imaging in which cytokine gene-transduced DCs were 
localized in, or in proximity to, apoptotic regions of the tumor, while control nontransduced DCs 
were rarely detected in injected tissues.  As expected, intratumoral delivery of these DCs induced 
more profound and poly-specific anti-tumor immune responses.  
We then sought to further evaluate the mechanism(s) by which DC mediated their 
tumoricidal activity, and whether this activity could be enhanced by pre-conditioning tumor 
cells.  The Fas-FasL pathway was demonstrated to play a dominant role in DC-mediated 
apoptosis of A20 lymphoma cells. Using a pharmacological agent PAPA-NO (an NO donor 
compound), we successfully showed that treated lymphoma cells were sensitized to DC-induced 
apoptosis, and that subsequently DC Ag uptake and cross-presentation to specific T cells were 
also markedly enhanced as a consequence. These findings argue for the development of 
combinational therapies integrating autologous DC injection into tumor lesions in concert with 
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 conditioning regimens that sensitize tumor cells to DC-mediated killing, in order to promote 
effective cross-priming of therapeutic anti-tumor T cells.   
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 2. Preface Chapter 2 
 
DC-based vaccines and therapies represent attractive strategies in the treatment of cancer. 
In the current study, murine bone marrow (BM) derived-DCs transduced with the mIL-12 and/or 
mIL-18 genes were used to vaccinate tumor-bearing mice, and the anti-tumor immune responses 
and tumor growth were evaluated.  In addition to expressing higher levels of MHC class I/II and 
costimulatory molecules, DCs engineered to secrete mIL-12 and/or mIL-18 displayed a dramatic 
increase in their tumoricidal activity against tumor cells in vitro.  This enhanced lytic capacity 
occurred in concert with elevated expression of multiple TNF family ligands on the cell surface 
of DCs. Blocking experiments using antagonist Abs to these ligands suggested a dominant role 
of TNFα, and possibly a minor role of TRAIL in DC-mediated killing of tumor cells. Using a 
confocal imaging technique, we confirmed that the cytokine engineering of DCs promoted DC 
survival, tumor apoptosis, and antigen uptake in situ.  Perhaps most importantly, intratumoral 
delivery of these engineered DCs significantly inhibited the growth of tumors in vivo when 
compared to delivery of control DC. Evaluation of the reactivity pattern of T cells in treated mice 
revealed that the repertoire of natural CMS4-derived peptide epitopes recognized by CD8+ T 
cells was dramatically expanded, in association with the observed improvement in disease 
course.  This suggests that cytokine gene-engineered DCs are more efficient in cross-presenting 
tumor-derived peptide epitopes to specific T cells in vivo, yielding a poly-specific immune 
response that is more effective in regulating tumor progression.   
 
This work has been published in Cancer Research (2003 Oct 1;63(19):6378-86). 
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2.1. Abstract 
Dendritic cells (DCs) were adenovirally-engineered to constitutively and durably secrete 
the potent Th1-biasing cytokines interleukin-12 (IL-12, AdIL12DC) and/or interleukin-18 (IL-
18, AdIL18DC) and evaluated for their ability to promote therapeutic anti-tumor immunity in 
murine sarcoma models.  Injection of either AdIL12DCs or AdIL-18DCs into day 7 CMS4 or 
MethA tumors resulted in tumor rejection or slowed tumor growth when compared with control 
cohorts.  Importantly, intratumoral injection with DCs engineered to secrete both IL-12 and IL-
18 (AdIL12/IL18DC) reduced tumor size and caused complete tumor rejection better than any 
other treatment group analyzed.  This strategy was also effective in promoting the regression of 
contralateral, untreated tumors.  Both CD4+ and CD8+ T cells were required for tumor rejection.  
CD8+ splenic T cells from mice treated with AdIL12/IL18DC displayed the broadest repertoire 
of Tc1-type reactivity to acid-eluted, tumor-derived peptides among all treatment cohorts.  This 
apparent enhancement in cross-presentation of tumor-associated epitopes in vivo may result from 
the increased capacity of engineered DCs to kill tumor cells, survive tumor-induced apoptosis 
and to present immunogenic MHC/tumor peptide complexes to T cells after intratumoral 
injection.  In support of this hypothesis, cytokine gene engineered DCs expressed higher levels 
of MHC and costimulatory molecules, as well as FasL and membrane-bound TNF-α, with the 
latter markers associated with elevated tumoricidal activity in vitro.  Cytokine gene-engineered 
DCs appeared to have a survival advantage in situ when injected into tumor lesions, to be found 
in approximation with regions of tumor apoptosis, and to have the capacity to ingest apoptotic 
tumor bodies.  These results support the ability of combined cytokine gene transfer to enhance 
multiple effector functions mediated by intralesionally injected DCs that may concertedly 
promote crosspriming and the accelerated immune-mediated rejection of tumors. 
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 2.2. Introduction 
Dendritic cells (DCs) effectively elicit primary, and boost secondary, immune responses to 
self and foreign antigens (19, 137).  Since these specialized APCs can induce the generation of 
both antigen-specific cytotoxic T lymphocytes (CTL) and T helper cells, DC-based vaccines are 
attractive strategies for the treatment of cancer. In this regard, DCs pulsed with tumor-associated 
antigens in various forms, including whole cell lysates (138, 139), peptides (140, 141), proteins 
(142), RNA (143) or DNA (144, 145), have proven effective in eliciting protective and 
therapeutic anti-tumor immunity in murine models.  The results of several DC-based tumor 
vaccine trials have also recently been reported in the setting of B-cell lymphoma, melanoma, 
prostate cancer, and renal cell carcinoma, among others (103, 146-148).  Although tumor-
specific T cells were promoted by vaccination in most patients, objective clinical responses have 
thus far only been observed in only a minority of treated individuals.  These modest current 
clinical successes for DC-based cancer vaccines would be expected to improve if study designs 
were modified for optimal DC promotion of Th1-type immunity in cancer-bearing hosts. 
Interleukin-12 (IL-12) exhibits a number of immunologically important activities, 
including the ability to enhance NK and CTL activities (149-151), and to polarize CD4+ T cell 
responses by supporting Th1/Tc1-type, and suppressing or repolarizing Th2-type immunity (152, 
153).  We and others have reported potent anti-tumor effects associated with IL-12 gene therapy 
using IL-12 gene modified tumor cells (154-156) and DCs (133), or systemic administration of 
IL-12 protein (130, 157) in murine tumor models.  Based on these results, phase I/II clinical 
trials of IL-12 gene therapy have been performed, with significant, but transient objective 
clinical responses reported to date (158).  
Interleukin-18 (IL-18) is a member of the IL-1 family of proinflammatory cytokines, 
produced by activated macrophages and DCs, that also appears to play an important role in 
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 driving Th1/Tc1-dominated immune responses (159-161).  Recently, IL-18 has also 
demonstrated potential as a biologic “adjuvant” in murine tumor models, with systemic 
administration of recombinant IL-18 or direct intratumoral injection of IL-18 adenoviral vector 
inducing significant anti-tumor effects in multiple murine tumor models (162-164).  Indeed, we 
have recently reported that intratumoral delivery of IL-18 gene transduced DCs can elicit anti-
tumor Th1-type immunity in association with enhanced therapeutic efficacy in the CMS4 tumor 
model (165).  
IL-12 acts synergistically with IL-18 by enhancing IFN-γ production from Th1/Tc1-type T 
cells (127, 128), thereby providing a strong rationale for the use of these factors in combined 
cytokine gene therapy (CGT) approaches.  While the coordinate administration of these two 
cytokines (as recombinant proteins) in murine tumor models has resulted in more potent anti-
tumor responses than that observed for the single agents, coadministration has also been 
associated with lethal organ damage and septic shock-like toxicities that appear attributable to 
the extremely high systemic levels of IFN-γ evoked by this strategy (163).  To overcome such 
systemic toxicities, we examined the effectiveness of therapies based on the injection of 
genetically-transduced DCs in order to provide paracrine secretion of IL-12 and/or IL-18 in the 
tumor-associated microenvironment.  We demonstrate that intratumoral delivery of DCs 
genetically modified to secrete both IL-12 and IL-18 safely induce accelerated tumor rejection, 
in association with stronger Type-1 immunity and a more diverse “therapeutic” repertoire of 
tumor-reactive, Tc1-type T cells in situ.   
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 2.3. Materials and methods 
 
2.3.1. Mice 
Six-to-eight week old female BALB/c mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME), and maintained in micro-isolator cages.  We generated the BALB/c.EGFP 
Transgenic (Tg) mice by 8 cycles of backcrossing C57BL/6-TgN(ACTbEGFP)1Osb mice 
(Jackson) onto the BALB/c background within the Central Animal Facility at the University of 
Pittsburgh.  Animals were handled under aseptic conditions per an Institutional Animal Care and 
Use Committee (IACUC)-approved protocol and in accordance with recommendations for the 
proper care and use of laboratory animals. 
 
2.3.2. Cell lines and cultures 
CMS4 and Meth A are chemically induced BALB/c sarcomas and have been described 
previously (166).  Cell lines were maintained in complete media (CM, RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 100U/ml penicillin, 100 µg/ml 
streptomycin and 10mM L-glutamine: all reagents from GIBCO/Life Technologies, Grand 
Island, New York) in a humidified incubator at 5% CO2 and 37°C. 
 
2.3.3. Generation of DCs in vitro from BM 
The procedure used in this study was as described by Son et.al. (167). Briefly, BALB/c or 
BALB/c.EGFP Tg bone marrow was cultured in CM supplemented with 1000U/ml of rmGM-
CSF and rmIL-4 (Schering-Plough, Kenilworth, NJ) at 37oC in a humidified, 5% CO2 incubator 
for 7 days. DCs were then isolated at the interface of 14.5% (w/v) metrizamide (Sigma, St 
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 Louis, MO) in CM discontinuous gradients by centrifugation. DCs typically represented >90% 
of the harvested population of cells based on morphology and expression of the CD11b, CD11c, 
CD40, CD54, CD80, CD86, class I and class II MHC antigens (data not shown). 
 
2.3.4. Viral vectors 
The mock adenoviral vector Adψ5 and the adenovirus encoding mouse IL-18 gene were 
used as previously described (165).  The Ad.mIL-12 was produced and provided by the 
University of Pittsburgh Cancer Institute’s Vector Core Facility as previously reported (168). 
 
2.3.5. Mouse IL-18 and IL-12 production from adenoviral transduced DCs 
Five million (day 7 cultured) DCs were infected with recombinant adenoviruses encoding 
mouse IL-18 (AdIL18), mouse IL-12 (AdIL12), both AdIL18 and AdIL12 or mock vector (AdΨ
5), as previously reported (165).  After 48 hr, adenoviral infected DCs were harvested and 
analyzed for phenotype and function.  Culture supernatants were also collected for measurement 
of mouse IL-18 and mouse IL-12 production using species specific IL-18 and IL-12p70 Enzyme 
Linked Immuno Sorbent Assay (ELISA) kits (BD-Pharmingen, San Diego, CA), with lower 
levels of detection of 31.5 and 62.5 pg/ml, respectively. 
 
2.3.6. Flow cytometry 
For phenotypic analyses of adenovirally infected DCs, PE- or FITC-conjugated monoclonal 
antibodies against mouse cell surface molecules [CD11b, CD11c, CD40, CD54, CD80, CD86, 
H-2Kd, I-Ad (all from BD-Pharmingen)], and appropriate isotype controls were used, and flow 
cytometric analyses were performed using a FACscan (Becton Dickinson, San Jose, CA) flow 
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 cytometer.  Cell surface expression of TNF family ligands was assessed using a previously 
described, highly sensitive, three-step flow cytometry technique (82).  First, adenovirally-
infected DCs were stained with anti-mouse TNF-related apoptosis-inducing ligand (TRAIL) 
antibody (e-Bioscience, San Diego, CA), anti-mouse Fas ligand (FasL) antibody (MBL, 
Medical&Biological Laboratories, Nagoya, Japan), anti-mouse TNF-α antibody (Endogen, 
Woburn, MA) or appropriate isotype-matched controls.  Second, the DCs were labeled with 
biotin-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA) and, third, were 
labeled with PE-conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA).  The 
results of flow cytometric analyses of TNF family ligand expression are reported in arbitrary 
mean fluorescence intensity (MFI) units. 
 
2.3.7. MTT assays 
To evaluate the cytotoxicity of control or genetically-engineered DCs against tumor cells, 
24 hr MTT assays were performed as previously described (49).  For blocking the interaction 
between the TNF family and its ligands, DCs were preincubated for 60 minutes with antagonist 
antibodies against TRAIL, Fas ligand or TNF-α (final concentration 20 µg/ml).   Effector DCs 
and targets were then mixed in a 5:1 (DC:T) ratio, and cytotoxicity assays were performed as 
described above (49). 
 
2.3.8. Animal experiments 
BALB/c mice were injected subcutaneously with 2x105 CMS4 or 5 x 105 MethA cells in 
the right flank on day 0.  On day 7, tumor size reached approximately 20-30mm2.  On day 7 and 
14, BALB/c mice were treated with intratumoral immunization of 1x106 adenoviral transduced 
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 DCs in a total volume of 100μl of phosphate-buffered saline (PBS).  Tumor size was assessed 
every 3 or 4 days and recorded in mm2 by determining the product of the largest perpendicular 
diameters measured by vernier calipers. Data are reported as the average tumor area ± SD.  To 
assess the impact of systemic immunity from vaccination, we examined the growth of 
contralateral, untreated tumors.  For the latter models, BALB/c mice were injected 
subcutaneously with 2x105 CMS4 cells in both flanks on day 0.  On day 7 and 14, 1x106 AdIL-
12 and AdIL-18 co-infected DCs (AdIL12/IL18DC) were injected in the tumor on the right flank 
and both tumors were measured every 3 or 4 days. 
To assess the fate and function of injected DCs, we generated day 7 BM-derived DCs from 
BALB/c.EGFP Tg mice and infected them with the Adψ5, AdIL-12, AdIL-18 or AdIL12 + 
AdIL-18 viruses as indicated above.  Forty-eight hours later, 1 x 106 control or virally-infected 
DCs were harvested, washed in PBS and injected into day 7 CMS4 tumors established in 
syngeneic BALB/c mice.  After 1 additional day, tumors were resected, fixed for 1h in 2% 
paraformaldehyde (in PBS) and then cryoprotected in 30% sucrose in PBS, prior to being shock 
frozen in liquid nitrogen-cooled isopentane.  Five micron frozen sections were then generated 
and incubated in a reaction mix containing 1 mM Cy3-conjugated UTP, 250 U/ml terminal 
transferase in 200 mM potassium cacodylate, 25 mM Tris, 20 mM cobalt chloride (Boehringer 
Mannheim, Indianapolis, IN).  After a 45-min incubation at 37oC the reaction was terminated by 
washing with PBS and counterstained with 2 mg/ml Hoechst 33258 (Sigma Chemical Co., St. 
Louis, MO) for 3 minutes.  The washed sections were then mounted in Gelvatol (Monsanto) and 
observed using an Olympus BX51 microscope equipped with a cooled CCD color camera.  
Images of TUNEL, EGFP, and Hoescht stained nuclei were collected. 
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 2.3.9. T-cell depletion experiments 
On days -1, 6, 11, 16 after tumor inoculation, mice were injected i.p. with 100 µl of PBS 
(control) or ascitic fluid of anti-CD4 (GK1.5 hybridoma, American-Type Culture Collection, 
ATCC, Rockville, MD), anti-CD8 (53-6.72 hybridoma, ATCC), or isotype control antibody 
(H22-15-5 hybridoma, ATCC).  The efficiency of specific subset depletions were validated by 
flow cytometry analysis of splenocytes using PE-conjugated anti-CD4 and anti-CD8 mAbs 
(Pharmingen).  In all cases, 99% of the targeted cell subset was specifically depleted (data not 
shown).   
 
2.3.10. Splenic CD8 + T-cell responses against CMS4 tumors and eluted naturally 
processed peptides derived from CMS4 cells 
Peptides were acid-eluted from viable CMS4 cells and separated on reverse-phase high-
performance liquid chromatography (RP-HPLC), as previously described (169).  Individual 
HPLC fractions were lyophilized to remove organic solvent and then reconstituted in 200μl of 
PBS and stored at -20°C until use.  Pooled CD8+ T cells were isolated to a purity of > 95% from 
the spleens of two treated mice/group seven days after the second DC injection (i.e. day 21 post-
tumor inoculation) using magnetic bead cell sorting (MACS; Miltenyi Biotec, Auburm, CA) and 
then co-cultured (1x105/well) with 1 x 104 irradiated (10,000 rads) CMS4 cells or syngeneic DCs 
(2x104/well) and HPLC-fractionated peptides in 96-well tissue culture plates.  After a 48hr 
incubation, culture supernatants were collected and analyzed for IFN-γ release using a 
commercial ELISA (BD-Pharmingen) with a lower limit of detection of 31.5pg/ml. Data are 
reported as the mean +/- SD of triplicate determinations.   
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 2.3.11. Statistical analyses 
All experiments with three or more groups in which treatment was applied as a completely 
randomly design, were first analyzed by a one way or two way factorial analysis of variance.  If 
the resulting p value was less than 0.05, specific pairwise contrasts were tested with a t test with 
Welch’s correction for unequal variance as needed.  Data were checked for distributional 
properties and appropriate transformations were applied.  Cytotoxicity was determined in repeat 
experiments in which results were expressed as a percentage of target cells killed.  These data 
were arcsin transformed and analyzed by a two way mixed model analysis of variance using 
experiments as a random effect.  Tests for between-group differences were subsequently 
stratified by experiments.  Analyses of IFN-γ production from splenocyte-derived T cell and 
expression of TNF family ligands were conducted with the exact Kruskal-Wallis test.  If the p 
value for the Kruskal-Wallis test was <0.05, a priori contrasts were evaluated with the Wilcoxon 
test.  The analysis of therapeutic single tumor inoculation murine treatment models was 
conducted with mixed linear models.  Data were log transformed, within-mouse covariance was 
estimated, and fixed effects of treatment were adjusted for random mouse effects.  Raw p values 
for comparing pairs of groups at a single time were adjusted by bootstrap resampling.  The 
growth of bilateral inoculated tumors was analyzed by a two-way fractional fixed effects model.  
Tumor rejection rates were fit to a generalized linear model (with binomial link) that 
incorporated treatment group, day of observation, and their interaction. 
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 2.4. Results 
 
2.4.1. Cytokine production by, and phenotype of, adenovirally infected DCs.   
 We initially validated IL-12 and IL-18 production from adenovirally infected DCs (Table 
1).  As expected, DCs infected to produce both IL-12 and IL-18 (AdIL12/IL18DC) secreted 
significant quantities of both murine IL-12 and IL-18, respectively (Table 1).  The culture 
medium of mIL-18 cDNA transfected DCs (AdIL18DC) contained mIL-18, but also a 
significantly elevated quantity of IL-12p70.  In contrast, the culture medium of IL-12 transfected 
DCs (AdIL12DC) contained significant quantities of IL-12, but no detectable IL-18.  Finally, the 
supernatants derived from control Adψ5DC did not contain detectable levels of either IL-12 or 
IL-18.  Analyses of the supernatants harvested from engineered DCs over time indicated that 
DCs secreted peak levels of IL-12 and/or IL-18 two days after infection with AdIL12 or AdIL18, 
but that they continued to produce statistically elevated levels of these cytokines for up to 10 
days post-transfection (data not shown). 
A flow cytometric examination of the impact of IL12 and/or IL18 cDNA insertion on DC 
phenotype was then performed 48h after adenoviral infection.  AdIL12/IL18DCs displayed 
significantly elevated levels of the MHC class I/II and CD86 costimulatory molecules and 
AdIL18DCs exhibited elevated levels of the MHC class I/II, CD80 and CD86 molecules, when 
compared to either Adψ5 control virus infected DCs or non-infected DCs (DC), with these two 
control groups yielding indistinguishable results (Table 2).  In contrast, among the markers 
analyzed, AdIL12DC expressed increased levels of MHC class I and class II, but not 
costimulatory, molecules when compared to control DCs (Table 2). 
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 2.4.2. Increased expression of TNF family ligands on adenoviral infected DCs.  
Human DCs express several TNF family ligands, including FasL, TRAIL, TNF-α and LT-
α1β2, and can implement these in mediating the apoptotic death of tumor cells in vitro and in 
vivo (49, 50).  Our pilot studies indicated that mouse DCs have similar properties, and that Th1-
biasing cytokine (such as IL-12 or IL-18) gene transfer into DCs might enhance the anti-tumor 
effector function of DCs (133, 164).  Based on these findings and considerations, we evaluated 
the impact of cytokine gene insertion on DC expression of FasL, TRAIL and TNF-α.  As shown 
in Figure 5, non-infected DCs express a basal level of TRAIL, FasL and TNF-α on their cell 
surface; with the expression level of TRAIL being very low, while FasL and TNF-α are 
expressed at comparatively moderate levels.  While Adψ5 infection of DCs did not result in any 
modulation of TRAIL, FasL or TNF-α expression, both FasL and TNF-α were increased in 
intensity on the cell membrane of AdIL12/IL18DC, AdIL18DC and AdIL12DC when compared 
to Adψ5 or non-infected DCs (p=0.0286). TRAIL expression by AdIL12/IL18DC was also 
significantly elevated vs. non-infected DCs (p=0.0286), while AdIL12- or AdIL18-infection of 
DCs did not result in statistically significant alternation in expression of TRAIL. 
 
2.4.3. Cytokine gene-engineered DCs exhibit improved tumoricidal activity in vitro and 
enhanced survival/effector function in vivo.   
We next examined the tumoricidal activity of adenovirally-infected DCs against CMS4 
cancer cells using 24hr MTT assays.  Non-infected DCs (DC) or Adψ5 DC displayed 
approximately the same levels of killing activity (Figure 6A), suggesting that adenoviral 
infection alone did not modulate this DC function.  In contrast, AdIL12DC and AdIL12/IL18 
(but not AdIL18DC) were significantly better killers of CMS4 target cells on a cell-per-cell 
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 basis, than Adψ 5DC or non-infected DCs (all p<0.01).  Combined infection of DCs with both 
AdIL-12 and AdIL-18 yielded the highest level of cytotoxicity observed for any DC effector cell 
group tested in these analyses, with this increased cytotoxicity significantly better than the AdIL-
18DC, Adψ5DC or control DCs cohorts (all p < 0.05), but not the AdIL12DC group (p = 0.71).  
We observed a similar order: AdIL12/IL18DC > AdIL12DC > AdIL18DC > Adψ5DC or DC at 
various times in a 42 day experiment evaluating the in vitro tumoricidal activity of DC effector 
cells against the MethA sarcoma (data not shown). 
To determine the role of TNF family ligands in DC-mediated cytotoxicity, we performed 
24 hr MTT assays in the presence of antagonist antibodies (Figure 6B).  AdIL12/IL18DC-
mediated cytotoxicity against CMS4 cells was significantly decreased when anti-TRAIL or anti-
TNF-α antibodies were applied (p<0.0001), while blocking anti-FasL antibody had little effect.  
When all three blocking antibodies were added, DC-mediated cytotoxicity was decreased by 
approximately 50% (p<0.0001).  These results demonstrate that AdIL-12 and/or AdIL-18 
infection enhances the cytotoxic activity of DCs against CMS4 cells, with both TRAIL and 
TNF-α playing significant roles in this effector function. 
To assess the impact of cytokine gene engineering on DC stability and function within the 
tumor microenvironment in situ, we first generated BM-derived DCs from BALB/c.EGFP 
transgenic (EGFP Tg) mice, infected these DCs with Adψ5, AdIL-12 and/or AdIL-18 and 
injected 1 x 106 of these engineered (or control uninfected) DCs into the lesions of syngeneic 
BALB/c mice bearing day 7 CMS4 tumors.  Twenty-four hours later, tumors were resected, 
fixed, sectioned and counterstained for TUNEL+ apoptotic cells.  As shown in Figure 7 (panels 
A-C), tumors injected with PBS, uninfected DCs or Adψ5DCs failed to contain either EGFP+ 
(51) DCs and a limited number of TUNEL+ (red) apoptotic tumor cells.  In marked contrast, we 
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 were able to detect EGFP+ DCs in tumors if these DCs had been infected with AdIL-12 and/or 
AdIL-18 prior to injection (Figure 7, panels D-F).  These viable EGFP+ DCs were typically 
localized in, or proximal to, regions of increased tumor apoptosis, with some injected DCs 
containing apoptotic tumor bodies (Figure 7D).       
 
2.4.4. Intratumoral delivery of DCs engineered to secrete IL-12 and/or IL-18 is 
therapeutic in the CMS4 tumor model.   
Based on our observation that cytokine gene engineered DCs exhibit increased survival and 
tumoricidal activity, and hypothesizing that this might yield a mechanism that would enhance the 
cross-priming of anti-tumor T cells in vivo, we next examined whether IL-12 gene and/or IL-18 
gene transfer enhanced the therapeutic potential of DCs delivered intratumorally in the CMS4 
tumor model.  BALB/c mice were injected subcutaneously with 2x105 CMS4 cells.  On day 7, 
these tumors exhibited a mean tumor area of 20-30 mm2.  Tumor-bearing mice were then treated 
by intratumoral injection of 1x106 AdIL12/IL18DC, AdIL12DC, AdIL18DC, Adψ5DC or PBS.  
As shown in Figure 8A, the growth of CMS4 tumors in mice treated with AdIL12/IL18DC, 
AdIL12DC or AdIL18DC was significantly inhibited when compared with tumors in the mice 
treated with the control protocols (p< 0.05 on days 14 through 42 vs. Adψ5DC or PBS).  Both 
AdIL12/IL18DC (at all time points after day 7) and AdIL12DC (from day 21 through 42) 
produced significantly greater anti-tumor effects than AdIL18DC, with AdIL12/IL18DC yielding 
greater therapeutic benefit than AdIL12DCs from day 10 through day 24 (all p<0.05).  Although 
intratumoral injection of Adψ5 infected DCs did not lead to complete regression of established 
tumors in any instance, tumor growth was significantly inhibited (p< 0.05 from day 28 through 
day 42) when compared to mice treated with PBS only.  As shown in Figure 8B, the highest 
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 observed rate of tumor rejection occurred in mice treated with AdIL12/IL18DC, with all mice 
rejecting their tumors by day 24 (95% confidence interval for the percentage of rejected tumors = 
54% to 100%).  Eighty-three percent (i.e. 10 of 12) of mice treated with AdIL12 DC and 33% 
(i.e. 4 of 12) of mice treated with AdIL18DC also ultimately rejected their tumors.  These results 
demonstrated that either IL-12 or IL-18 gene transfer can enhance the therapeutic effects of DC-
based therapy against established CMS4 tumors, and that injection of DCs engineered to secrete 
both IL-12 and IL-18 accelerates the therapeutic effectiveness of this treatment strategy.  We 
obtained similar results in a homologous treatment model for the MethA sarcoma, with AdIL-
12/IL-18DC-based therapies proving statistically superior (p< 0.05) to AdIL-12DC-, AdIL18DC-
, or Adψ5DC-based therapies until day 28 (Figure 8C).  
To prove that the therapeutic benefit of our AdIL12/IL-18DC-based regimen in the CMS4 
tumor model was T cell-dependent, we performed T cell subset depletion studies (Figure 8D).  
Both CD4+ and CD8+ T cell depletions significantly inhibited the therapeutic efficacy of 
intratumoral injections with AdIL12/IL18DCs (p < 0.05 at all time points after day 7).   
 
2.4.5. DCs are required for the observed efficacy of AdIL-12/IL-18DC-based 
intratumoral therapy.   
To prove that DCs play a requisite role in the observed therapeutic benefit associated with 
combined IL-12 + IL-18 cytokine gene therapy, we performed additional control experiments in 
the CMS4 tumor model.  Mice bearing established day 7 CMS4 tumors were injected with PBS, 
AdIL12/IL18DCs or AdIL-12 (5 x107 pfu) + AdIL-18 (2 x 108 pfu) adenoviruses.  The amount 
of each adenovirus injected was equivalent to the total amount of each virus used to generate the 
AdIL12/IL18DCs applied in the comparitor cohort.  As shown in Figure 9, AdIL12/IL18DCs, 
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 but not the combined adenoviruses promoted the rapid rejection of CMS4 tumors after they were 
administered intratumorally.   
 
2.4.6. Intratumoral injection of AdIL12/IL18DC enhances Tc1-type anti-tumor T cell 
responses.   
 Based on our in vivo depletion data, we next evaluated whether the therapeutic benefits 
observed in our DC-based treatment regimens were associated with the degree of anti-CMS4 
effector CD8+ T cell generation in treated animals.  CD8+ T cells were MACS-isolated from 
splenocytes 14 days after the final intratumoral injections of DCs and then co-cultured with 
irradiated CMS4 tumor cells for 5 additional days.  CD8+ T cells obtained from mice treated 
with the AdIL12/IL18DC regimen produced substantially elevated levels of the Th1/Tc1-
associated cytokine IFN-γ vs. CD8+ T cells obtained from mice treated with any other DC-based 
regimen or with PBS only (Figure 10).  IFN-γ production differed significantly among groups 
(p=0.0011, exact two tailed Kruskal-Wallis test).  Although there were too few mice to conclude 
significant differences between pairs of treatments, the higher observed level of IFN-γ 
production by Tc1-type CD8+ T cells elicited in response to CMS4 tumor cells in vitro after 
treatment with AdIL12/IL18DC suggests there may be an association with the degree of 
therapeutic effects observed in this system. 
 
2.4.7. Splenic CD8+ T cells isolated from mice treated with intratumoral injections of 
AdIL12/IL18DC react against an expanded array of CMS4-derived peptide epitopes.   
To evaluate the repertoire of CMS4-derived peptide epitopes recognized by Tc1-type T 
cells in treated tumor-bearing mice, IFN-γ production was measured by ELISA after co-culture 
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 of splenic CD8+ T cells with syngeneic DCs pulsed with peptides that had been acid-eluted from 
CMS4 cells and subsequently separated using reverse-phase HPLC.  As shown in Figure 11, 
CD8+ T cells harvested from mice treated with the AdIL12/IL18DC regimen reacted against a 
wide range of HPLC fractions containing CMS4 peptides.  CD8+ T cells isolated from animals 
treated with AdIL12DC or AdIL18DC injections reacted against a more limited set of HPLC 
fractionated CMS4 peptides, and in cases where common fractions were recognized by T cells 
from mice in all of the cytokine gene engineered DC treatment cohorts, the magnitude of IFN-γ 
production in the AdIL12/IL18DC group was typically highest.  CD8+ T cells from mice treated 
with Adψ5DC or PBS responded poorly to CMS4 fractionated peptides.  These results suggest 
that the therapies based on intratumoral delivery of DCs modified by IL-12 and IL-18 gene 
transfer can amplify and expand the repertoire of Tc1-type, anti-tumor CD8+ T cell responses in 
association with increased therapeutic benefit. 
 
2.4.8. Both locoregional and systemic therapeutic anti-tumor immunity is induced by 
intratumoral injection with AdIL12/IL18DC.   
Since the broadest and strongest Tc1-type, anti-tumor T cell responses were induced in 
AdIL12/IL18DC-treated animals, we next chose to analyze whether the treatment of a CMS4 
lesion in one flank would impact the progression of contralateral, untreated CMS4 tumors.  
Bilateral tumors were established in BALB/c mice for 7 days.  On days 7 and 14, tumors 
established in the right flank of these animals were injected with AdIL12/IL18DC, Adψ5DC or 
PBS.  Tumors on the left flank remained untreated.  As shown in Figure 12, both the treated and 
non-treated tumors in mice receiving the AdIL12/IL18DC regimen were significantly smaller on 
days 14 through the chosen endpoint of these experiments on day 28 (all p<0.01) when compared 
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 with tumors in mice treated with either PBS or the Adψ5DC regimen, and in 2/5 cases, animals 
in the AdIL12/IL18DC treatment group were rendered tumor-free by day 21. 
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 2.5. Discussion 
In the current study, mice bearing established CMS4 or MethA sarcomas were treated with 
intratumoral injections of syngeneic DCs engineered to constitutively and durably secrete the 
Th1-biasing cytokines IL-12 +/- IL-18.  We theorized that cytokine gene engineered DCs would 
survive longer and be capable of mediating tumoricidal activity, tumor apoptotic body uptake 
and subsequent “cross-priming” of tumor-reactive T cells in the tumor-draining LN and spleen of 
treated animals.  Therapy-associated, cross-primed T cells would exhibit an expanded repertoire 
of anti-tumor specificities that could theoretically be more effective in mediating tumor 
regression. 
Our results demonstrate that established CMS4 or MethA tumors may be therapeutically 
treated by intratumoral injection with either IL-12 and/or IL-18 cDNA transfected DCs (but not 
control DCs), suggesting that Th1-cytokine gene transfer into DCs enhances their anti-tumor 
efficacy in this tumor model. Importantly, tumors injected with DCs engineered to secrete both 
IL-12 and IL-18 regressed most acutely of all treatment groups and were statistically superior to 
either the AdIL12DC or AdIL18DC until day 24, when the AdIL12DC (but not the AdIL18DC) 
cohort was provided a comparable level of therapeutic benefit.  While we would hypothesize that 
the superior impact of AdIL12/IL18DC therapy requires co-transfection of DCs to produce IL-12 
and IL-18, we have not yet formally evaluated whether the intratumoral injection of AdL12DC 
and AdIL18DC (i.e. single cytokine cDNA transfectants) yields a similar favorable outcome.  
Subsequent analyses revealed that the anti-tumor efficacy associated with intralesional 
AdIL12/IL18DC therapy; 1) requires both CD4+ and CD8+ T cells based on the results of T cell 
subset depletion experiments, 2) requires DCs and cannot be reproduced by simple intratumoral 
injection of AdIL-12 + AdIL-18 viruses, and 3) is correlated with the induction of a strong Tc1-
40 
 type, anti-tumor T cell responses.  These latter Tc1-type responses were polyspecific in nature 
based on the ability of isolated immune CD8+ T cells to recognize and secrete IFN-γ in response 
to a broad array of HPLC-resolved CMS4 peptides when presented by syngeneic DCs in vitro.   
While a surprising number of HPLC fractions containing CMS4-derived peptides were 
recognized by CD8+ T cells from AdIL12/IL18DC treated mice when presented by DCs, these T 
cells did not react against all fractions, nor did they react against control, non-pulsed DCs.  We 
are currently in the process of determining which peptide-containing fractions recognized by 
these “therapeutic” T cells are idiotypic to the CMS4 sarcoma and which fractions contain shared 
sarcoma epitopes by analyzing a corresponding peptide fractionation derived from alternate H-2d 
tumors, including the MethA sarcoma, the Renca renal cell carcinoma and the TS/A mammary 
carcinoma.    
Importantly, experiments in a bilateral tumor model suggest that treatment of a single 
lesion by intratumoral delivery of AdIL12/IL18DC promotes the regression of both treated and 
non-treated, contralateral tumors, supporting the ability of this treatment protocol to induce 
systemic anti-tumor immunity as noted above.  It should be noted, however, that contralateral 
tumors regressed at a slower rate than treated lesions, suggesting that additional DC- and/or T 
cell-dependent effects beyond those linked to the induction of systemic anti-tumor effector T 
cells were in play within tumors directly injected with AdIL12/IL18DC. Induction of TNF 
family ligand expression could be either due to the direct effect(s) of IL-12 and IL-18 on DCs or 
to the indirect effects of IL-12/IL-18-induced factors secreted by NK cells or other 
contaminating cells in the DC preparations analyzed. Moreover, the impact of locally co-
produced IL-12 and IL-18 would be expected to be multifunctional and one must consider the 
ability of these cytokines to inhibit angiogenesis, promote the production of IFN-γ-dependent 
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 chemokines and lymphocytic infiltration, and maintain immune effector function(s) within the 
typically immunosuppressive or pro-apoptotic tumor microenvironment (170-173).  Indeed, we 
have observed that injected cytokine gene engineered DCs exhibit improved viability within the 
tumor site in vivo, arguably allowing these cells to generated and acquire apoptotic tumor bodies 
and to extend the window of time during which they may productively cross-prime anti-tumor T 
cells in situ.  We are currently performing extensive kinetic experiments to determine the fate 
and migration patterns of control vs. engineered DCs in/to draining LN after their injection into 
tumor lesions to partially address this issue.   One would also hypothesize that given extended 
durability in cytokine production by injected AdIL12/IL18DC within the treated lesion, that 
increases in inflammatory cell infiltrates and the resistance of these cells to tumor-induced 
apoptosis would be likely, based on the underlying immunobiologies of IL-12 and IL-18 (15, 
174, 175).  Interestingly, our finding that AdIL18DCs produce not only elevated levels of IL-18, 
but also IL-12 may prove be important in discerning the mechanisms by which AdIL18DC-based 
therapy is at least partially effective in our sarcoma models.  Currently, there is no literature to 
support or refute the ability of IL-18 to elicit IL-12 production from DCs.  However, DCs 
isolated from mice deficient in functional p38 MAP kinase are impaired in their ability to 
produce IL-12 (176) and IL-18 is known to activate p38 MAP kinase in murine DCs (177).  
Hence, it is conceivable that IL-18 produced by AdIL-18DCs may act in an autocrine fashion to 
facilitate IL-18R+ DC production of IL-12p70. This assumption could be tested by 
demonstrating the expression of IL-18R on DCs using Abs against IL-18R. Alternatively or 
additionally, AdIL18DC may produce more IL-12 due to indirect effects, such as IL-18 induced 
production of IFN-γ from contaminant (< 5%) activated T or NK cells, with subsequent IFN-γ 
promotion of a more DC1-type phenotype (178).  
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 In addition to their well-publicized roles in antigen cross-presentation, DCs injected 
directly into tumor lesions may mediate direct tumoricidal activity as a result of their expression 
of TNF family ligands, including TNF-α, lymphotoxin (LT)-α/β, TRAIL, and FasL (49, 50).  
Indeed, in the current study, we have not only demonstrated that DCs engineered to secrete IL-12 
and/or IL-18 (but not control DCs) express significantly higher levels of MHC and costimulatory 
molecules, but also elevated levels of membrane-bound TNF-α and FasL.  MTT assays revealed 
that DCs infected with AdIL-12 and/or AdIL-18, especially DCs coinfected with AdIL-12 and 
AdIL-18, mediated enhanced cytotoxicity against CMS4 cells in vitro, and that this killing was 
partially blocked with anti-TRAIL and anti-TNF-α antagonist monoclonal antibodies.  The 
residual DC-mediated killing of tumor cells that cannot be blocked by the mixture of blocking 
anti-TNF-α, anti-FasL and anti-TRAIL Abs may be due to the influence of DC expressed LT-α/β 
that were not evaluated using blocking antibodies in this study.   These findings suggest that IL-
12 and IL-18 gene transfection into DCs can enhance the ability of these cells to directly kill 
cancer cells via certain TNF family ligands, and that this mechanism may be relevant to the 
effective generation of apoptotic tumor bodies (as evidenced in our CMS4 imaging studies) 
providing tumor antigen for subsequent DC cross-presentation to specific T cells in vivo.  We are 
currently evaluating this issue in the CMS4 and MethA models using intratumoral injected DCs 
generated from gld (Fas-L deficient), LT-α -/-, LT-β -/-, TNF-α -/- and LT-α/β-TNF triple KO 
mice.  Preliminary evidence continues to support a dominant role for TNF-α in DC-mediated 
killing of these tumors in vitro and in situ.   In this context, it is important to delineate potential 
importance of DC membrane-associated vs. secreted TNF-α as a tumoricidal effector molecule.  
While rTNF-α (at doses up to 1000 U/ml) induced a maximum of approximately 30% and 10% 
apoptosis of CMS4 and MethA tumor cells in 24h MTT assays, respectively (data not shown), 
43 
 this level of killing was far inferior to that mediated by cytokine gene modified DCs in the 
current report.  
In spite of recent progress and some early success reported for DC-based cancer 
immunotherapies, there is a great need to improve this therapeutic strategy.  We have shown here 
that combinational adenoviral-based IL-12 and IL-18 gene transfer into DCs results in an 
improved therapeutic reagent capable of promoting enhanced anti-tumor efficacy in vivo when 
injected directly into tumor lesions. This paracrine delivery strategy was chosen since significant 
toxicities have been previously reported for combined rIL-12 + rIL-18 systemic therapy in 
murine tumor models (163) and similar complications might be anticipated in prospective human 
clinical trials.  While serum IFN-γ levels became transiently elevated in mice 2 days (i.e. at the 
peak of transfected DC production of IL-12/IL-18 in vitro) after each intratumoral injection of 
AdIL-12/IL-18DC (when compared to Adψ5DC or control PBS injected mice), this only 
approached a maximal level of 400 pg/ml of serum (data not shown).  This degree of systemic 
IFN-γ was approximately equal to that observed in the asymptomatic rIL-12 group reported by 
Osaki et al. (163) and was far less than the pathologic 17 ng/ml levels of serum IFN-γ noted for 
toxic rIL-12 + rIL-18 administration (163).  Given this modest level of systemic IFN-
γ production and our inability to discern any treatment-associated modulation in animal behavior 
or physical appearance, we believe that intralesional AdIL-12/IL-18DC therapy is not only very 
effective, but safe.  Our findings support intralesional delivery of DC-based, IL-12/IL-18 gene 
therapies as therapeutic regimens for cancer.  
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 3. Preface Chapter 3 
 
In this chapter, we further evaluated mechanism(s) of DC-mediated tumoricidal function 
against cancer cells and whether cancer cells could be sensitized to this activity, thereby 
increasing the efficacy of DC-based therapies. The initial set of experiments showed that DCs 
could mediate apoptosis in lymphoma cell lines via both Fas-FasL-dependent and -independent 
pathways, with the former playing a more dominant role. To modify the sensitivity of tumor cells 
to apoptosis, we chose to pre-treat them with a pharmacological agent, an NO donor compound 
PAPA-NO. This agent is a protein phosphatase inhibitor that alters protein phosphorylation 
status, and thus promotes the proteasomal degradation of certain cellular proteins. Here we 
observed the preferential turnover of the anti-apoptotic protein survivin in A20 lymphoma cells 
treated with NO donors through a proteasome-dependent pathway.  In association with the down-
regulation of survivin, we noted enhanced sensitivity of tumor cells to DC-induced apoptosis.  
This activity involved the concerted action of multiple TNF ligand/receptor pathways, including 
FasL/Fas, TRAIL/TRAIL-R, and possibly TNF/TNF-R as well. More importantly, NO treatment 
facilitated DC uptake of tumor apoptotic bodies and the subsequent cross-presentation of tumor 
derived-antigens to specific T cells.  
 
This work has been published in Cancer Research (2005 Sep 15;65(18):8461-70). 
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 3.1. Abstract 
 
        Dendritic cells (DCs) are professional antigen-presenting cells (APCs) associated with 
efficient antigen processing and presentation to T cells. However, recent evidence also suggests 
that DCs may mediate direct tumoricidal functions. In this study, we investigated the mechanism 
by which murine DCs mediate the apoptotic death of murine lymphoma cell lines, and whether 
DC effector function could be enhanced by pre-conditioning tumor cells with the protein 
phosphatase (PP) inhibitor nitric oxide (NO) by altering the balance of pro-/anti-apoptotic 
proteins in the treated cells. We observed that NO donor compound sensitized lymphomas to 
DC-mediated cytotoxicity in vitro. Both immature and spontaneously matured bone marrow-
derived DCs (SM-DC) were capable of inducing tumor cell apoptosis, with SM-DCs serving as 
comparatively better killers. Fas ligand (FasL)-Fas engagement proved important in this activity, 
since elevated expression of membrane-bound FasL was detected on SM-DCs, and DCs derived 
from FasL-deficient mice were less capable of killing NO-sensitized tumor cells than wild-type 
DCs. As FasL-deficient DCs were still capable of mediating a residual degree of tumor killing, 
this suggests that FasL-independent mechanisms of apoptosis are also involved in DC-mediated 
tumor killing. Since NO-treated tumor cells displayed a preferential loss of survivin protein 
expression via a proteasome-dependent pathway, enhanced tumor sensitivity to DC-mediated 
killing may be associated with the accelerated turnover of this important anti-apoptotic gene 
product. Importantly, NO-treated tumor cells were also engulfed more readily than control tumor 
cells and this resulted in enhanced cross-presentation of tumor-associated antigens to specific T 
cells in vitro. 
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 3.2. Introduction 
 
  Dendritic cells (DCs) are the most efficient antigen presenting cells (APCs) and appear 
largely responsible for the induction of primary immune responses (19). In a tumor-bearing host, 
DCs are believed to cross-present tumor peptide epitopes in the context of major 
histocompatibility complex (MHC) class I and class II molecules in order to stimulate specific 
(CD8+ and CD4+) CTL responses, respectively. Interestingly, apoptotic tumor cells have been 
reported to provide DCs with a comprehensive source of tumor antigens used to cross-prime 
effector T cells (179, 180). The origin of apoptotic tumor bodies in situ has been generally 
presumed to be the result of spontaneous tumor cell death or to be mediated by cytotoxic effector 
NK or T cells. However, tumor infiltration by these two killer cell populations may not be a 
common event early in tumor progression and cross-priming would occur more efficiently if 
DCs themselves were able to directly induce tumor cell apoptosis as an innate function, thereby 
generating an antigenic substrate for consequent T cell cross-priming in situ.   
  It has been previously demonstrated that human DCs, particularly after treatment with pro-
inflammatory cytokines, are capable of mediating the in vitro apoptosis of tumor cells via a 
mechanism involving membrane-bound Fas ligand (FasL) or TNF-related apoptosis inducing 
ligand (TRAIL) (43-46). Recently we reported that immature human DCs are preferentially able 
to directly induce the apoptotic death of cancer cell lines and fresh tumor cells in vitro. This 
cytotoxicity was antagonized by inclusion of blocking Abs or receptor-Fc constructs specific to 
TNF family ligands, demonstrating that human immature DCs mediate tumoricidal activity by 
simultaneous engagement of multiple transmembrane TNF family ligands, TNF, FasL, LTα1/β2 
and TRAIL (49, 50). In the current report, we have determined that spontaneously matured 
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 murine bone marrow-derived DCs (SM-DC) are superior to immature DCs in mediating the 
apoptotic death of B and T lymphoma cells in vitro.   
   Since our current observations and previous reports (44-46) suggest that DC-mediated 
killing of tumor cells in vitro was most evident at high DC-to-tumor cell ratios, which may not 
accurately reflect the physiological situation where low frequencies of tumor infiltrating DCs are 
observed (181), we sought means by which tumor cells could be further sensitized to this lytic 
pathway in order to define a potentially translatable therapy for established cancers. In particular, 
we chose to sensitize tumor cells to DC-mediated apoptosis by pharmacologically altering the 
balance of the anti-/pro-apoptotic protein expression in tumor cells using a nitric oxide (NO) 
donor compound PAPA-NO. This agent is capable of oxidizing and ablating the enzymatic 
activity of protein phosphatases (PP) that regulate the proteasome-dependent turnover of many 
cellular proteins (182-185), including the pro-/anti-apoptotic proteins in the Bcl-2 and the 
inhibitor of apoptosis (IAP) families, as well as the inhibitor nuclear factor- κB (IκB) (186-189). 
In the present study, we report that NO induces the enhanced proteasome-dependent degradation 
of survivin in tumor cells, in association with the increased sensitivity of treated tumor cells to 
DC-mediated apoptosis and uptake, leading to enhanced cross-presentation of tumor cell-
expressed antigens to specific T cells in vitro. 
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 3.3. Materials and methods 
 
3.3.1. Mice 
        Female 6-8-week old BALB/c mice and FasL-deficient (gld) mice on the BALB/c 
background were purchased from the Jackson laboratory (Bar Harbor, ME) and maintained in 
microisolator cages. Animals were handled under aseptic conditions per an institutional Animal 
Care and Use Committee-approved protocol and in accordance with recommendations for the 
proper care and use of laboratory animals. 
 
3.3.2. Cell lines and culture 
        The A20 cell line is an H-2d B lymphoma cell line (American Tissue Culture Collection, 
Manassas, VA). The EL4 cell line is an H-2b T lymphoma cell line and EG7 is a derivative of 
EL4 cells that contains the chicken ovalbumin (OVA) transgene (190) both cell lines were the 
kind gifts of Dr. Louis Falo III, University of Pittsburgh). All cell lines were maintained in 
complete media (CM; RPMI-1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 10mM L-glutamine; all reagents from Invitrogen, Carlsbad, CA) and 50µM 2-
mercaptoethanol (2-ME; Sigma Chemical Co., St. Louis, MO) at 5% CO2 and 37ºC in a 
humidified incubator. The mock- and mouse FasL-transfected L5178Y T lymphoma cell lines 
were obtained from Dr. Hideho Okada. The cells were cultured in CM supplemented with 1mM 
sodium pyruvate and 0.1mM non-essential amino acid (both reagents from Invitrogen). G418 
sulphate (Geneticin, from Invitrogen) was used at 1 mg/ml for maintenance of the transfected 
line. The DO11.10 cell line is a T cell hybridoma that recognizes I-Ad MHC class II/OVA 
peptide323-339 complex (a generous gift from Dr. Louis Falo III).  This CD4+ T cell line was 
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 maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 10mM L-glutamine. 
 
3.3.3. Peptides 
        The OVA323-339 and control C. Falciparum (MCS326-345) I-Ad binding peptides were 
synthesized using 9-fluorenylmethoxycarboxyl (fMOC) chemistry by the University of 
Pittsburgh Cancer Institute’s (UPCI) Peptide Synthesis Faculty.  The peptides were >95% pure 
based on high-performance liquid chromatography, with identities validated by mass 
spectrometric (MS/MS) analyses performed by the UPCI Protein Sequencing Facility.   
 
3.3.4. Generation of DCs in vitro from bone marrow (BM) 
        DCs were generated as previously described (167). Briefly, BALB/c BM cells were cultured 
in CM supplemented with 1000 U/ml recombinant murine granulocyte/macrophage colony-
stimulating factor (mGM-CSF; Schering-Plough, Kenilworth, NJ) and 500 U/ml recombinant 
mIL-4 (Peprotech Inc., Rocky Hill, NJ) at 37ºC in a humidified, 5% CO2 incubator for 7 
(immature) or 9 (mature) days. DCs were then purified using CD11c magnetic beads (MACSTM; 
Miltenyi Biotec., Auburn, CA) and subjected to the phenotypic and functional analyses described 
below. In some experiments, an additional metrizamide gradient centrifugation (167) was 
performed prior to CD11c MACSTM isolation, resulting in purities exceeding 99% (Supplement 
figure 1).   
 
3.3.5. Experimental design of nitric oxide sensitization of tumor cells 
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         Tumor cells were pretreated with the NO donor compound PAPA-NO (a generous gift from 
Dr. Lawrence Keefer, National Cancer Institute, Bethesda, MD). After 1h incubation, the media 
were removed and cells maintained in fresh media for additional 18h at 37ºC. The cells were 
then harvested and used as targets in cytotoxicity assays or lysed for Western blot analyses. 
 
3.3.6. Flow cytometry 
        For phenotypic analyses of DC, PE- or FITC- labeled monoclonal antibodies (mAbs) 
against mouse cell surface molecules I-Ad, CD80, CD86 and appropriate isotype controls (all 
purchased from BD-Pharmingen, San Diego, CA) were used. Flow cytometric analyses were 
performed using a Coulter Epics XL (Beckman Coulter, Fullerton, CA) flow cytometer. To 
assess cell surface expression of Fas or FasL, a previously described three-step flow cytometric 
technique (82) was used. Briefly, the DC were labeled with unconjugated anti-mouse FasL mAbs 
or appropriate isotype-matched controls (MBL, Medical & Biological Laboratories, Nagoya, 
Japan), washed twice and incubated with biotin-conjugated secondary Abs (Vector Laboratories, 
Burlingame, CA), washed twice, then labeled with PE-conjugated streptavidin (Jackson 
ImmunoResearch, West Grove, PA). Results are presented as overlays of single-color 
histograms, with mean fluorescence intensity (MFI) units reported on an arbitrary scale.  
        To evaluate the cytotoxicity of DC against A20 tumor cells, DC were co-cultured with 
tumor cells for 4h at an effector/target (E:T) ratio of 5:1 at 37ºC. The cells were then harvested 
and stained with PE-conjugated anti-mouse B220 mAb (BD-Pharmingen) and FITC-conjugated 
pan-caspase inhibitor z-VAD-FMK (Promega, Madison, WI) on ice for 30min. The results are 
reported based on the percentage of cytotoxicity calculated as the number of apoptotic tumor 
cells (B220+VAD-FMK+) divided by total number of tumor cells (B220+). To block the 
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 interaction between the TNF family ligands and their receptors, DC were preincubated for 1h 
with antagonist Abs against TRAIL (e-Bioscience, San Diego, CA) and/or TNFα (Endogen, 
Woburn, MA) or appropriate isotype control Abs at a final concentration of 20 µg/ml (49, 191). 
Effector DC and targets were then mixed at a 5:1 (DC/tumor) ratio and cytotoxicity assays 
performed, as described above. To test the cytotoxicity of DC against normal B cells, bulk 
splenocytes were cultured at 37ºC in the presence of 10µg/ml LPS. Three days later, cells were 
harvested and treated with or without PAPA-NO at a final concentration of 25 µg/ml, with 
cytotoxicity assays performed, as described above.  
  To evaluate antigen uptake, untreated or PAPA-NO treated tumor cells were stained with 
Hoechst 33342 (Molecular Probe, Carlsbad, CA) for 30m prior to co-culture with DCs for 18h at 
a DC/tumor ratio of 5 to 1. DC uptake of Hoechst-positive tumor cells by DCs was then analyzed 
using a MoFlo cytometer (Cytomation, Fort Collins, CO). 
 
3.3.7. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays 
        To assess the apoptotic sensitivity of A20 cells to agonist anti-mouse Fas mAb (Jo2; BD-
PharMingen), A20 cells were cultured in the presence or absence of the Ab at the indicated 
concentrations for 24h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays 
(MTT) assays were then performed, as described previously (49). Briefly, the Experimental 
wells (Ex) contained medium and both A20 tumor cells and Ab. Wells with medium alone were 
used as background control (BG) and wells for total viability/spontaneous death of untreated 
cells (TS) contained only medium and A20 cells. The percentage of cytotoxicity was calculated 
using the following formula: %cytotoxicity = [(TS-BG) – (Ex-BG)]/(TS-BG)×100%. 
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 3.3.8. In vitro antigen cross-presentation assays 
        EG7 and EL4 cells were pretreated with PAPA-NO prior to coculture with DCs for 24h, 
36h or 48h at a DC/tumor ratio of 5 to 1. DO11.10 T hybridoma cells were then added to wells at 
a T/DC ratio of 1 to 1. After 18h, the supernatants were harvested and IL-2 production was 
quantitated by specific ELISA (Endogen, Woburn, MA). IL-2 secretion by hybridoma cells 
stimulated with DCs pulsed with 400 ng/ml of the OVA323-339 synthetic peptide served as a 
positive control in these experiments.    
 
3.3.9. Western blot analyses 
        A20 cells were treated with PAPA-NO as described above. The cells were next washed in 
PBS and lysed in buffer (1% Triton X-100, 0.5% NP-40, 3.7 mg SOV, 150 mM NaCl, 1 mM 
EDTA, 10 mM Tris; all reagents from Sigma) containing protease inhibitors (Complete, Roche 
Diagnostic, Mannheim, Germany). Total cellular lysate from each sample was separated by 12% 
SDS-PAGE electrophoresis, prior to transfer to a PVDF membrane (Millipore, Bedford, MA), 
and incubation of the blots with anti-survivin, anti-Bcl-2, anti-Bcl-XL and anti-Bax Abs (all 
purchased from Santa Cruz Biotechnology, Santa Cruz, CA) in 2% non-fat dry milk in 0.5% 
Tween 20 in PBS. After 3 washes, the membrane was incubated with appropriate HRP-conjugate 
mouse or rabbit secondary Abs (Biorad, Hercules, CA). Bound Abs were detected using an ECL 
chemiluminescence detection kit (PerkinElmer, Boston, MA). Mouse anti-β-actin Ab (Abcam, 
Cambridge, MA) was used as a loading control. Densitometric quantitations were performed 
using a White/UV Transilluminator (UVP Products, Upland, CA) and analyses performed using 
Labworks software (UVP). 
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        For the functional analyses of proteasome involvement, A20 cells were pretreated with 
PAPA-NO. One hour later, media were removed and cells maintained in fresh culture for 
additional 4h in the presence or absence of proteasome inhibitor lactacystin (concentration, 0.2 
µM or 1 µM; Sigma). Cells were lysed and immunoblots were performed as described above.   
 
3.3.10. Statistical analyses 
  Statistical differences between groups were evaluated using a two-tailed Student’s t test, 
with statistical significance defined as a p value < 0.05. 
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 3.4. Results 
 
3.4.1. Spontaneously matured bone marrow-derived murine DCs (SM-DC) mediate 
superior killing of tumor cell lines 
  Based on our previous report that cultured human monocyte-derived DCs were capable of 
mediating the apoptotic death of tumor cell lines in vitro (49), we analyzed whether BM-derived 
murine DCs generated in GM-CSF + IL-4 supported cultures were similarly capable of killing 
murine tumor cells. Approximately 30 × 106 CD11c+ (MACS-isolated; 90-95% pure) DCs per 
BALB/c donor mouse were obtained reproducibly on day 7 (immature; i.e. iDC) and day 9 
(spontaneously matured; i.e. SM-DC) of culture. SM-DCs expressed markedly higher levels of 
MHC class II molecules (I-Ad) and costimulatory molecules (CD80 and CD86) than their 
immature day 7 counterparts (Figure 13A).  
  Since our recent studies demonstrated a role for TNF family ligands expressed on human 
iDCs in the direct anti-cancer effector function mediated by these cells (50), we assessed the 
potential role of the murine homologues in DC-mediated killing of the A20 B lymphoma cell 
line. As it has been reported that activated B cells express abundant membrane-bound Fas and 
are sensitive to Fas-mediated apoptosis (192), we initially targeted an analysis of the FasL-Fas 
pathway. Compared with expression on the FasL-transfected L5178Y (L5178.FasL; positive 
control) cell line, FasL expression on DCs was clearly evident, albeit at a lower level (Figure 
13B). Notably, SM-DCs expressed higher levels of FasL than iDCs, indicating that SM-DCs 
might be more effective at inducing the apoptotic death of Fas+ tumor cells. To test this 
hypothesis directly, we incubated A20 tumor cells with either iDC or SM-DCs for 4h at 37oC at 
an DC/T ratio of 2.5 to 1 or 5 to 1. Cells were then stained with antibodies against the B cell 
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 marker B220 to distinguish tumor cells from DCs, in addition to the fluorescent caspase substrate 
z-VAD-FMK to detect apoptotic cells. As shown in Figure 14, in the absence of DCs, only 5.4% 
of A20 cells were determined to be undergoing spontaneous apoptosis. However, co-cultures of 
DCs and A20 cells contained significantly greater frequencies of apoptotic A20 cells. Of interest, 
killing was DC dose-dependent and regardless of the E/T ratio evaluated, SM-DCs were more 
cytotoxic against A20 cells than iDCs.  Since effector cell function appeared to correlate with the 
relative expression level of membrane-bound FasL, these data suggest an important functional 
role for FasL in DC-mediated tumor cell apoptosis.    
        To provide further support for the role of the Fas-FasL pathway in DC-mediated 
tumoricidal activity, we analyzed A20 tumor cells for their level of expression of membrane-
bound Fas by flow cytometry. We detected uniform, high levels of Fas expression on the surface 
of A20 cells (Figure 15A). However, since expression of Fas is necessary, but not sufficient for 
cells to undergo Fas-mediated apoptosis (192), we also determined whether ligation of Fas could 
trigger A20 cells to become apoptotic (in 24h-MTT assays) after addition of various 
concentrations of agonist anti-Fas Ab (Jo2) to cultures. As shown in Figure 15B, the anti-Fas Ab 
induced A20 cell death in a dose-dependent manner, while the isotype-matched control Ab had 
little impact on A20 viability. Similarly, nearly 30% of A20 cells became apoptotic after a 4h co-
incubation with L5178Y.FasL cells but not control L5178Y cells (Figure 15C). These data 
demonstrate that A20 tumor cells were sensitive to the apoptosis mediated through FasL-Fas 
pathway induced by Ab agonist, FasL+ transfected cell lines or FasL+ DCs. 
  As a further demonstration of the relevance of FasL in DC-mediated tumor killing, and to 
determine whether additional Fas-independent pathways were also involved in this effector 
mechanism, we assessed the tumoricidal activity of BM-derived DCs generated from FasL-
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 deficient mice. While DCs generated from wild-type animals efficiently induced the apoptosis of 
A20 cells, DCs derived from FasL-deficient mice had approximately 3-fold less tumor cell 
killing capacity (Figure 16). These data indicate that FasL plays a dominant role in DC-mediated 
tumor apoptosis and that Fas-independent pathway(s) may also partially contribute to this killing 
activity. 
 
3.4.2. Pre-treatment of A20 tumor cells with a nitric oxide donor increases their 
sensitivity to DC-mediated, Fas-dependent apoptosis 
        Since A20 cells were moderately sensitive to Fas-dependent killing mediated by DCs, we 
next sought to determine whether tumor cells could become conditionally sensitized to such 
killing using pharmacologic agents.  In particular, we chose to attempt to alter the balance of 
anti-/pro-apoptotic protein expression in tumor cells by either up-regulating the expression of 
pro-apoptotic proteins or down-regulating anti-apoptotic proteins, or both, in order to 
theoretically make the cells more susceptible to DC-mediated apoptosis. We attempted to 
modulate this balance by affecting the functional activity of protein phosphatases (PP) that 
regulate the levels of pro-/anti-apoptotic protein expression based on their state of 
phosphorylation, making them targets for E3 ligases and consequently, the proteasome (193). 
Since NO is known to oxidize critical cysteine residues within PP catalytic sites, we pretreated 
A20 cells with the NO donor compound PAPA-NO for 1h and then maintained the cells in fresh 
media for an additional 18h. The cells were then stained with FITC-conjugated pan-caspase 
inhibitor z-VAD-FMK to determine the level of cellular apoptosis. As shown in Figure 17, as a 
single agent, PAPA-NO induced apoptosis in A20 cells in a dose-dependent manner. More 
importantly, at low concentration (i.e. < 100 µg/ml), PAPA-NO was non-toxic, and did not 
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 promote significant A20 apoptosis by itself. However, the NO-conditioned tumor cells appeared 
to become sensitized to apoptosis mediated by anti-Fas agonist Ab (Figure 18A) or 
L5178Y.FasL cells (Figure 18B). 
  We next determined whether NO-pretreated A20 cells were also sensitized to DC-
mediated apoptosis. Figure 19A provides the cumulative results derived from three independent 
experiments performed. We observed that although treatment with the NO donor was non-toxic 
to A20 cells, it greatly enhanced their sensitivity to iDC-mediated apoptosis. Tumor cells pre-
treated with 25 µg/ml and 50 µg/ml of PAPA-NO showed significant differences in their 
apoptotic frequencies versus the non-treated tumor control group (p≤0.05). Similar results were 
also obtained using SM-DCs as effector cells (Figure 19B). Given minor concerns that the small 
contaminant CD11c-neg cell populations might be at least partially responsible for mediating 
tumor cell apoptosis, we performed an additional density gradient centrifugation step using 
metrizamide prior to CD11c MACS bead selection. This resulted in CD11c+ DC purities 
exceeding 99%, with no significant change in tumoricidal function mediated by these effector 
cells (Supplement figure 1).  
  Given additional concerns that such pre-conditioning could also affect the sensitivity of 
normal tissue targets to DC-mediated killing, we analyzed whether SM-DCs could promote the 
apoptotic death of normal B cells or B cells pre-treated with a source of NO. B cell blasts were 
generated from BALB/c splenocytes cultured with LPS for 3 days. As shown in Figure 20, SM-
DCs did not induce apoptosis in normal B cell blasts and B cell pre-treatment with PAPA-NO 
did not increase the observed activated caspase staining when compared with controls.  
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 3.4.3. Sensitization of A20 cells to DC-mediated apoptosis by NO involves both Fas-
dependent and -independent pathways 
  Since DC killing of A20 cells appeared to be at least partially mediated through a Fas-
dependent pathway, we initially hypothesized that this would also be the case for NO-treated 
tumor cells. Indeed, the capacity of DCs generated from FasL-deficient mice to kill NO-treated 
A20 cells was greatly impaired when compared with DCs derived from wild type mice (Figure 
21A). These results suggest that the Fas-FasL mediated pathway contributes partially to the 
observed tumoricidal activity associated with DCs.  At the same time, these data also suggest the 
FasL-independent pathway(s) are also significantly involved in DC-mediated killing of A20 
tumor cells. The most likely potential candidates would be other TNF family members, such as 
TNFα and TRAIL, based on our previous results published for human DCs (50).   
  To test these possibilities, we performed blocking experiments to interfere with the residual 
tumor cell killing associated with FasL-deficient DCs using antagonist Abs. DCs generated from 
FasL-deficient mice were pre-incubated with individual or combinations of Abs specific for 
either TNFα or TRAIL, prior to addition to NO-pretreated A20 tumor cell cultures. As shown in 
Figure 21B, disruption of either TNF/TNF-R or TRAIL/TRAIL-R interactions served to further 
(partially) inhibit DC-mediated killing of NO-treated A20 cells. In this setting, anti-TNFα Ab 
appeared less effective than anti-TRAIL Abs in blocking the residual killing mediated by FasL-
deficient DCs. Indeed, since the simultaneous disruption of all three ligand-receptor (FasL/Fas, 
TNF/TNF-R, TRAIL/TRAIL-R) pairs appeared to inhibit DC-mediated killing of NO-treated 
A20 cells to a degree comparable to that noted for DCs whose FasL and TRAIL interactions 
were simultaneously disrupted, TNFα likely plays a very minor role in this model of apoptosis.  
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   Combined with the fact the NO treatment did not modulate the expression of TNF family 
receptors (TNF-R, Fas, TRAIL-R) on A20 cells (data not shown), these data suggest that pre-
treatment of A20 with NO donors sensitizes these target cells not only to FasL-induced apoptosis, 
but also to (at least) TRAIL-mediated apoptosis. However, the minor but detectable level of 
apoptosis observed under conditions in which the Fas, TNF and TRAIL pathways were 
coordinately blocked may suggest the further, minor participation of additional molecule(s) in 
DC tumoricidal activity.  
 
3.4.4. Treatment of tumor cells with NO donors preferentially accelerates survivin 
degradation through a proteasome-dependent pathway in association with enhanced 
sensitivity to DC. 
        To further investigate the mechanism(s) by which NO donors sensitize A20 tumor cells to 
DC-mediated killing, we analyzed the NO-treated tumor cells for alterations in their expression 
of pro- and anti-apoptotic proteins. One of most well-known protein families that regulate cell 
survival and apoptosis is the Bcl-2 family, in particular, Bcl-2 and Bcl-XL (194). The protective 
function of these proteins is, in great part, due to the formation of inactivating heterodimers with 
the pro-apoptotic protein Bax. An imbalance among these proteins, in favor of the pro-apoptotic 
activities, might sensitize tumor cells to apoptosis. However, we did not observe any differences 
in the normalized (vs. β-actin) expression levels of the Bcl-2, Bcl-XL or Bax proteins within 18h 
of NO treatment (Figure 22A). In contrast, we noted that expression of another anti-apoptotic 
protein, survivin, which belongs to the IAP family, was markedly down-regulated in an NO 
donor dose-dependent manner (Figure 22A).  
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  Since the degradation of survivin is ubiquitin-proteasome dependent (195), we assessed 
whether the NO-induced effects on tumor cell survivin expression could be inhibited by the 
proteasome inhibitor lactacystin. A20 cells that were treated with NO donors alone exhibited 
50% reduction in survivin expression by 4h post-treatment, with lactacystin completely blocking 
this process (Figure 22B).  Indeed, even control A20 tumor cells treated with lactacystin 
displayed a slight elevation in their expression of survivin, indicating that constitutive survivin 
turnover is blocked by this agent. 
 
3.4.5. Pre-treatment of tumor cells with NO donor results in increased DC uptake and 
cross-presentation of tumor antigen to specific T cells.   
        We further hypothesized that increased ability of DC to mediate the apoptotic death of NO-
treated tumor cells might lead to a more efficient protocol for apoptotic body (ApB) uptake and 
consequent cross-presentation of tumor antigens in vitro. To properly evaluate uptake of ApB by 
DCs using a flow cytometry-based analysis, we chose to pre-label tumor cells for 30m with the 
cell-permeable, UV-fluorescent nucleic acid dye Hoechst 33342. After staining with Hoechst 
33342, tumor cells were washed and cultured in media for an additional 3h to allow for any 
unbound dye to diffuse from the cells. To validate that the staining procedure did not promote 
tumor cell apoptosis directly, labeled tumor cells were cultured overnight, then stained with PI to 
evaluate viability. At a final concentration of 4 µg/ml Hoechst 33342, 100% of tumor cells were 
stained and this signal was maintained for at least 24h, without any alteration in cell viability.  
Moreover, labeling was stable, since the supernatant harvested from labeled cells was not able to 
consequently label fresh tumor cells (data not shown).  
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        To evaluate ApB uptake by DCs, we treated tumor cells with PAPA-NO, stained them with 
Hoechst 33342 before addition of DCs, and 24h later, harvested these cultures for flow 
cytometric analyses. Cells were counterstained with anti-mouse B220 mAb (to distinguish A20 
cells from DC) and PI. Viable DCs (PI-B220-) were gated and analyzed for uptake of Hoechst 
33342+ apoptotic bodies. As shown in Figure 23A, DCs co-cultured with NO-treated A20 cells 
exhibited much higher MFI than those cultured with untreated tumor cells. This suggests that 
more apoptotic tumor cells were taken up by DCs per unit time if the tumor cells were pretreated 
with the NO donor compound.  
        We next asked whether this NO-dependent uptake of tumor cells would result in the 
improved cross-presentation of tumor-associated antigens to specific T cells. To test this, we 
used an OVA model antigen system; H-2b OVA-expressing EL4 (EG7) tumor cells and the 
DO11.10 T cell hybridoma that recognizes the OVA323-339 peptide epitope presented in the 
context of I-Ad. As was the case for A20 B lymphoma cells, both EL4 and its derivative T 
lymphoma cell line EG7 were sensitized to DC-mediated killing by PAPA-NO pre-treatment 
(Figure 23B and supplement figure 2), providing support for the generality of this mechanism.  
Also similar to A20 cells, uptake of apoptotic EG7 cells by DCs was also increased if these 
tumor cells were pretreated with NO-PAPA (Figure 23C).  
        To access cross-presentation of tumor antigens to T cells, H-2b EG7 (OVA+) or EL4 (OVA-
) tumor cells were pretreated with PAPA-NO, prior to addition of H-2d DCs to culture. To allow 
for optimal antigen uptake, processing and presentation, we co-incubated the DC-tumor mix for 
24-48h, prior to addition of I-Ad-restricted DO11.10 T hybridoma cells. IL-2 production by the 
hybridoma cells was used as an indicator for T cell activation. As shown in Figure 24, T cells 
stimulated with DCs loaded with synthetic OVA323-339 peptide produced high levels of IL-2, 
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 while no response was detected for DCs pulsed with the control MCS peptide. Similarly, 
minimal IL-2 was produced when these T cells were cultured with DCs and EL4 (OVA-) tumor 
cells. On the contrary, when the EG7 (OVA+) tumor cells were pretreated with 10 or 25 µg/ml of 
PAPA-NO, IL-2 production from responder T cells was elevated to a level comparable to that of 
the DC + OVA323-339 peptide cohort and this level of production was significantly greater than 
that observed for T cells + DC + untreated EG7 cells (with maximal effects observed after 36-
48h processing periods). To further exclude the possibility of DC uptake of soluble OVA protein 
elaborated from EG7 cells, we also established trans-well cultures in parallel in which untreated 
of treated EG7 were added to upper wells while DCs and T cells were loaded into the bottom 
wells. Under these conditions, IL-2 was not detected in these cultures at any time point evaluated 
(data not shown), indicating that the activation of T cells in Figure 24 was primarily due to the 
direct cross-presentation of OVA peptide by H-2d DC uptake of ApB, which is accentuated by 
tumor cell pre-treatment with the NO donor compound.   
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 3.5. Discussion 
  In the current study, our central hypothesis was that apoptotic signals mediated via TNF 
family ligand/receptor complexes allow for DC-mediated tumor cell apoptosis, thereby defining 
a simplified cellular pathway capable of supporting the cross-priming of specific anti-tumor T 
cells. Our data provide novel information that multiple TNF family ligands participate in murine 
DC-mediated tumoricidal activity against B lymphoma cells in vitro; and, that this innate DC 
function can be further enhanced by pre-treating tumor cells with the phosphatase inhibitor NO 
to preferentially extinguish tumor cell expression of the anti-apoptotic protein survivin.  
  Previous reports have shown that FasL may be used by murine DCs to kill susceptible 
target cells, such as T cells (43, 88). Here, we report that multiple TNF family ligands, FasL and 
TRAIL (and possibly TNFα), participate in DC tumoricidal activity. Among the molecules that 
are involved, FasL clearly played a dominant role, since FasL-deficient DCs were reduced over 
65% in their killing capacity. Approximately 85% of the DC-mediated cytotoxicity was ablated 
when all three ligand/receptor (i.e. FasL, TRAIL, TNFα) pairs were simultaneouly disrupted. 
However, a low but detectable level of residual tumor cell apoptosis still remained under such 
conditions, suggesting the minor involvement of an as yet undefined molecule(s). While we were 
unable to assess its importance in the current study, one obvious candidate in this regard is 
lymphotoxin-α/β, which belongs to the same TNF ligand superfamily and has been reported to be 
utilized by human DCs to kill tumor cell lines in vitro (50).  
  Fas-induced apoptosis of B cells has been extensively evaluated in the past (196). Naïve 
murine B cells express low levels of Fas, but upon activation, expression of Fas is markedly up-
regulated (192). Notably, this is not sufficient to enhance B cell sensitivity to Fas-induced 
apoptosis. Engagement of B cell receptor or expression of anti-apoptotic proteins may induce 
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 resistance to Fas-mediated B cell death (196). Expression of p53 may also be required for B cells 
to undergo apoptosis. Crosslinking CD40 induces normal B cells to proliferate and differentiate 
but causes many tumor cell lines to undergo apoptosis. Murine B lymphoma lines that contain 
mutated p53, such as A20 cells, are induced to undergo apoptosis upon CD40 crosslinking, while 
other lines that express wild-type p53 are comparatively resistant (197). In this context, it is 
perhaps not surprising that we observed that murine BM-derived DCs were selectively cytotoxic 
against A20 B lymphoma cells and were non-toxic to normal naïve B cells or LPS-activated B 
cells (either not treated or pre-treated with NO donor compounds). This provides translational 
support that adoptively transferred DCs may selectively kill B lymphoma cells without damaging 
their normal counterparts in vivo. 
  Several groups have also shown that treatment of tumor cells with ionizing radiation, 
chemotherapeutic or other pharmacological agents can sensitize them to TNF family ligand-
induced apoptosis (135, 136, 198, 199). Our findings extend this work by suggesting that the pre-
treatment of tumor cells with a source of NO markedly increases their apoptotic sensitivity to 
DCs that express (at least) three TNF family ligands including FasL, TRAIL and TNFα. Since 
these molecules are coordinately utilized by CTLs (200, 201) and NK cells (82) to kill tumor 
cells, the in vivo treatment of tumor lesions with locoregional NO would be anticipated to 
sensitize tumor cells to not only DC-, but also to specific CTL- and NK-mediated apoptosis, 
particularly under pro-inflammatory, delayed-type hypersensitivity (DTH)-type conditions. 
  The mechanism by which NO sensitizes tumor cells to DC-mediated killing was also 
investigated. Among the anti-/pro-apoptotic proteins analyzed, survivin was found to be uniquely 
down-regulated after NO treatment. Survivin is a recently identified anti-apoptotic protein that is 
aberrantly expressed in cancer cells, but is not expressed by normal, differentiated adult tissues 
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 (202). Consistent with the homeostatic turnover/degradation of survivin being regulated by the 
ubiquitin-proteasome pathway (195), we observed that the proteasome inhibitor lactacystin 
blocked survivin degradation in NO-treated A20 cells. Based on our current data and previous 
reports (203, 204), we hypothesize that the mechanism of NO-induced survivin degradation and 
tumor sensitization involves the following pathway: 1) treatment of tumor cells with an NO 
donor compound rapidly inhibits the function of PP; 2) leading to the sustained activation of 
protein kinases, such as p34(cdc2)-cyclin B1, that are capable of phosphorylating survivin (203); 
3) enhanced phosphorylation of survivin facilitates its ubiquitination; and 4) its consequent 
proteasome-dependent degradation. As a result of altering the balance between anti- and pro-
apoptotic proteins towards a more pro-apoptotic phenotype, the death signals delivered by DCs, 
under such sensitized conditions, are enhanced. From an immunotherapeutic point of view, NO-
facilitated survivin degradation also provides an experimental basis for the design of new 
combinational therapy strategies in which a “sensitizing agent” and autologous DCs could be 
sequentially injected intratumorally. This would promote tumor cell death in an 
immunologically-important manner yielding enhanced DC-mediated cross-priming of specific T 
cells in vivo as supported in principle by the results of in vitro experiments reported in Figure 24. 
  Previous reports suggested the NO has a dichotomous nature. Instead of enhancing 
apoptosis, some groups showed that NO could inhibit apoptosis induced by different stimuli 
(205-208). These differences in behavior may be explained by the chemistry of NO. After the 
treatment of NO donor, released NO is thought to either react directly with radicals, or form 
intermediates that can facilitate nitrosylation reaction (209). Since various NO donors may 
induce either direct or indirect effects, this could yield different end effects on treated cells. For 
instance, it has been reported that pre-treatment of lung fibroblast cells with PAPA-NO and 
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 DEA-NO enhanced tumor sensitivity to cisplatin-mediated death, whereas other NO donors 
failed to do so (210). Hence, these distinct effects may be ultimately useful in defining clinical 
strategies for the use of NO donor compounds in cancer patients. 
  Since survivin is a shared tumor-associated antigen that is differentially expressed in a 
variety of malignancies and can be recognized by specific CTLs (211), it is also possible that 
proteasome-derived survivin peptides could be expressed at higher stochastic levels on NO-
treated tumor cells, making them better targets for specific T cell clearance. We are currently 
evaluating the ability of survivin peptide-specific CTLs to differentially recognize control vs. 
NO-treated tumor cells in vitro.   
   Somewhat in contrast to our previous studies of human DCs (49, 50), phenotypically 
mature murine DCs (i.e. SM-DCs), rather than immature murine DCs mediated superior levels of 
tumor cell killing. Since the lytic capacity of SM-DCs appeared comparable to that of LPS-
matured DCs (data not shown), the manner in which DCs become “mature” may not profoundly 
influence this functional aspect of these APCs.  
   Of translational importance, SM-DCs and iDCs appeared equally capable of engulfing 
apoptotic tumor bodies after first mediating their demise (data not shown). Given that DCs may 
also acquire antigens from viable cells (212), we could not formally exclude the participation of 
this pathway in the observed DC antigen uptake. Furthermore, our data has shown that 
sensitization of tumor cells to DC-mediated killing by NO donor treatment also leads to 
enhanced ApB uptake and cross-presentation of tumor-associated antigens to tumor-specific T 
cells. This provides confidence that the adoptive transfer of SM-DCs +/- NO intratumorally may 
lead to improved cross-presentation of tumor-derived epitopes to T cells in vivo. The co-
application of NO in situ may also impact DC function however, as suggested by an equivocal 
68 
 literature. Hence, although one group has showed that glioma induces apoptosis in DCs via 
inducible NO synthase (213), others have presented contradictory data that NO-treated DCs not 
only reduced the growth of the highly tumorigenic and poorly immunogenic B16 melanoma, but 
also caused tumor regression and improved animal survival (214). Clearly the direct testing of 
such combinational therapies in murine tumor models warrants further evaluation. 
  In summary, our study demonstrates that murine DCs mediate tumor cell apoptosis, and 
that such lysis may be increased by tumor cell pre-treatment with NO-elaborating agents in 
association with the depletion of tumor cell survivin protein levels. These findings provide a 
better understanding of important connections between the innate and adaptive immune effector 
functions of DCs and provide support for the development and pre-clinical testing of 
combinational immunotherapy approaches integrating tumor cell apoptosis-sensitization 
regimen(s) and intratumoral DC administration. 
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 4. SUMMARY AND CONCLUSIONS 
This thesis has considered the working hypothesis that DCs can directly mediate tumor 
apoptosis and then uptake, process and cross-present tumor Ags, allowing for the definition of an 
efficient system of cross-priming for poly-specific, anti-tumor T cells in situ.  Ultimately, I 
believe that by further studying the mechanism(s) of DC tumoricidal activity and the means to 
enhance this effect through tumor cell sensitizing modalities, we will gain a better understanding 
of the important connection between innate and adaptive immune functions associated with DCs 
in the tumor setting.  Furthermore, we may then have a rationale for the formulation of novel 
DC-based therapies for cancer.  
With regard to enhancing the efficiency of DC-mediated tumor apoptosis, I believe there 
are 2 prime approaches that should be considered. One is through DC modification. Gene-
engineered DCs have been shown to promote DC survival, antigen presentation, as well as T cell 
stimulation, depending on the gene(s) inserted. In our case, I chose two intriguing Type-1 
cytokines, murine IL-12p70 and IL-18. Transduction of one/both of these genes was shown to 
significantly improve DC cytotoxicity against CMS4 tumor cells in vitro. Genetic alteration was 
also associated with enhanced DC survival and antigen uptake, as well as notable therapeutic 
benefit in vivo. An alternative approach is via the sensitization of tumor cells to non-transfected, 
cultured DC-mediated apoptosis. A lack of balance in anti-/pro-apoptotic protein expression in 
tumor calls has been shown to alter their relative level of resistance to apoptosis. Accordingly, 
over-expression of pro-apoptotic proteins or down-regulation of anti-apoptotic proteins would be 
expected to sensitize tumor cells to apoptotic stimuli. In this study, we treated tumor cells with a 
pharmacologic NO donor compound, PAPA-NO, in order to accelerate the turnover of an anti-
apoptotic protein survivin.  I was able to demonstrate that pretreatment of lymphoma cells with 
PAPA-NO significantly increased their sensitivity to DC-mediated apoptotic death. This 
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 consequently resulted in an enhanced antigen uptake and cross-presentation of tumor antigen-
derived epitopes to specific T cells.  
Previous reports have shown that human DCs expressing TNF family ligands are capable 
of inducing apoptotic death in tumor cell targets. Hence, I decided to examine whether the 
induced expression of TNF family ligands on murine DCs would modulate their ability to kill 
tumor cells. Since pro-inflammatory cytokines have been reported to increase cellular expression 
of TNF family ligands, I initially sought to determine whether the molecular engineering of DCs 
to secrete the pro-inflammatory cytokines IL-12p70 and/or IL-18 would prompt the expression 
of TNF family ligands on DCs, and whether these engineered DCs would mediate an enhanced 
capacity to kill tumor cells. Importantly, it had been previously shown that delivery of DCs 
expressing IL-12 (133) or IL-18 (165) into tumor lesions could induce anti-tumor immune 
responses, although the mechanism(s) of their enhanced therapeutic activity had not been 
elaborated. The fact that these cytokines also act in a synergistic manner to enhance IFN-γ 
production from Th1/Tc1-type T cells provides a strong basis for the use of both factors in a 
combined immunotherapy.  Combining the available aggregate data, we hypothesized that 
infection of DCs with Ad.IL-12p70 and/or Ad.IL-18 would enhance their constitutive 
tumoricidal activity and that treatment of tumor bearing mice with cytokine-engineered DCs 
would induce both a stronger and also broader Type-1 anti-tumor immune response in situ, 
culminating in tumor regression. 
Indeed, my initial study was to generate mIL-12 and/or mIL-18 secreting DCs.  Following 
the previous protocol (165), I was able to successfully transduce mIL-12 and/or mIL-18 cDNAs 
into DCs, resulting in abundant production of rmIL12/rmIL-18, as confirmed by specific ELISA 
assays. Flow cytometric analyses indicated that these gene-modified DCs exhibited a more 
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 mature phenotype than control DCs, as they expressed higher levels of MHC class I/II, as well as 
costimulatory molecules, when compared to controls.  
To assess whether these DCs had become better killer cells, we next evaluated the cell 
surface expression of three TNF family ligands, TNF-α, FasL and TRAIL. These molecules are 
known for their ability to deliver death signal to target cells, and have typically been linked to the 
lytic capacity of other well-known killer cells, such as NK cells and cytotoxic T cells. Although 
non-infected, control DCs expressed low-to-moderate (i.e. baseline) levels of TNF family 
ligands, DCs infected with Ad encoding cytokines expressed significantly enhanced levels of all 
three molecules. This suggested that the cytokine gene-transduced DCs might represent more 
potent in their capacity to kill target cells that express the corresponding death receptors; i.e. 
TNF-R, Fas, or TRAIL-R.  
To directly test this possibility, we performed MTT assays in order to determine the 
comparative tumoricidal activities of the various DC populations. The MTT assay is based on the 
cleavage of the yellow tetrazolium salt, MTT, into purple formazan by metabolically-active cells, 
and thus, was initially designed to provide a quantitative index of cellular proliferation and 
viability. Here, this assay was modified to evaluate the cytotoxicity of effector cells (49).  I was 
very pleased to find that, although viral infection itself did not modulate DC killing activity, 
AdIL12DCs and AdIL12/IL18DCs became significantly better killers of CMS4 target cells in 
vitro. Inhibition of their killing activity using anti-TNF, anti-FasL, and/or anti-TRAIL blocking 
Abs demonstrated that both TNF-α and TRAIL played significant roles in this DC effector 
function. These data support the hypothesis that DC-mediated tumoricidal activity can be 
significantly enhanced by inserting the genes encoding IL-12 and/or IL-18 into DC, resulting in 
elevated expression of TNF family ligands by these APCs.  
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 These results also encouraged me to further investigate the functionality and therapeutic 
efficacy of cytokine engineered-DCs in situ. To observe the direct impact of these DCs in the 
tumor microenvironment, DCs were injected intratumorally into established subcutaneous 
tumors. One day post treatment, tumor apoptosis was evaluated using the TUNEL assay. In order 
to distinguish the injected DCs from host DCs, I specifically chose DCs generated from the bone 
marrow of BALB/c.EGFP Tg mice, where the cells are constitutively flourescent. The results 
turned out to be striking. While very few DCs or apoptotic tumor cells were found in tumors that 
had been injected with PBS, or with uninfected or Adψ5DCs, we were able to detect markedly 
increased frequencies of tumor apoptosis in lesions that were injected with IL-12 and/or IL-18 
transduced DCs.  This was strongly correlated with a remarkable number of viable DCs localized 
in or proximal to regions of increased tumor apoptosis. These data suggested that the engineering 
of DCs to secrete IL-12 and/or IL-18 might not only enhance the stability of DC (i.e. their 
capacity to resist tumor-induced apoptosis/necrosis), but also improve the killing activity of these 
APCs (on a per-cell basis) against tumor target cells.  
Another interesting finding in these experiments was the observation that some of the 
injected cytokine engineered-DCs could be imaged with engulfed apoptotic tumor bodies. This 
was in accordance with my hypothesis that an enhancement in the tumoricidal activity of DCs 
would directly translate into increased amounts of apoptotic bodies/debris, that could be taken up 
by the injected DCs in situ.  Given that my experiment focused on a single time point post-DC 
injection, a more comprehensive dynamic experiment should be performed in the future where 
both tumor and draining LN are harvested at 4, 8, 12, and 24 hours post-DC injection and tissues 
evaluated for both tumor apoptosis and DC uptake of tumor debris in tissue sections.  Such 
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 information will be useful in determining the actual kinetics of ApB generation and uptake by 
injected DC.  
These intriguing observations prompted me to further examine the therapeutic potential of 
DCs after ex vivo IL-12 and/or IL-18 gene transfer. As expected, intratumoral delivery of 
AdIL12/IL18DC, AdIL12DC, or AdIL18DC significantly inhibited tumor growth, when 
compared with the control uninfected DC treated cohort of animals, with AdIL12/IL18DCs 
proving statistically superior to either the AdIL12DC or AdIL18DC treatment cohorts. An 
evaluation of therapy-induced CD8+ T cell reactivity against natural CMS4-derived peptide 
epitopes revealed a markedly amplified and expanded Tc1-type repertoire in mice treated with 
gene-modified DCs, particularly for the AdIL12/IL18DC treated cohort. Given my in vitro 
results, I believe that this enhanced cross-priming of poly-specific T cells in vivo is likely due to 
the improved killing ability and stability of the injected DCs. Compared with previous reports 
that have focused on eliciting therapeutic T cell responses against a (single) specific tumor-
associated antigen (106-109),  my DC-based vaccine successfully induced much broader anti-
tumor T cell responses against multiple, tumor-associated antigens/epitopes. Therefore, it was 
not surprising to find that not only the treated tumors, but also contralateral untreated tumors 
were significantly inhibited in their progression, given the expectation that not only locoregional 
but systemic therapeutic immune responses were promoted by our novel DC-based therapies.   
       In addition to gene modification to directly improve killing activity of DCs, the next 
phase of my studies was to consider increasing tumor cell sensitivity to DC-mediated apoptosis 
to ultimately amplify the ability of intratumorally-delivered DCs to kill treated tumor cells, then 
cross-prime anti-tumor T cells in vivo.  I initially analyzed the constitutive tumoricidal activity of 
wild-type, cultured DCs. For this purpose, I chose a B lymphoma cell line, A20, as a primary 
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 tumor target, since our pilot study showed that this cell line was at the high end of sensitivity to 
DC-mediated apoptosis among all the cell lines that I tested. In addition, in order to characterize 
whether there was any correlation between the level of DC maturation and their killing ability, I 
analyzed both immature (d7) and spontaneously-matured (d9) cultured DCs as effector cells.  I 
observed that mature DCs were better killers of A20 cells, with this enhanced capacity associated 
with higher levels of FasL expression, when compared to immature d7 DCs.  These data contrast 
somewhat with human DC reports (49) and suggest that spontaneous maturation of murine DC 
does not negatively impact DC-mediated tumoricidal activity.   In follow-up experiments, I 
determined that FasL plays an important role in DC-mediated A20 tumor killing. Not only did 
A20 express uniformly high levels of Fas, but these cells were also sensitive to death signals 
delivered through the FasL-Fas pathway. This is perhaps best illustrated using DC generated 
from gld mice in which the APCs are deficient in expression of FasL.  Gld DC were largely 
deficient in their killing ability to kill A20 cells, suggesting a dominant role of FasL in this DC 
effector function.  
Next, I wished to explore a way to conditionally increase the sensitivity of tumor cells to 
DC-mediated apoptosis. Since the sensitivity of tumor cells to apoptotic stimuli was closely 
related to the balance of anti-/pro-apoptotic protein expression, we theorized that alteration of 
this balance using pharmacological agents could sensitize tumor cells to DC-mediated apoptosis. 
This idea was inspired by a series of preliminary experiments in our lab showing that treatment 
of human renal cell carcinoma cell lines with protein (tyrosine) phosphatase (PTP/PP) inhibitors 
could conditionally induce the degradation of a number of cellular proteins via the proteasome 
pathway, and others had shown that a subset of the sensitive proteins were involved in the 
apoptosis pathway of cell death.   
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 NO is reported to effectively and reversely inhibit PTP/PPs by oxidizing critical cysteine 
residues in the catalytic site. Despite its dichotomous nature, our data showed NO induced A20 
cell apoptosis in a dose-dependent manner. Of interest, at low concentrations, this drug was 
nontoxic and did not promote significant A20 apoptosis by itself.  While non-toxic, I 
hypothesized that this low dose of drug might have affected the balance of pro-/anti-apoptotic 
proteins in A20 cells, in a manner that might sensitize these targets to DC-mediated killing.  
Among the four proteins tested, treatment of A20 cells with PAPA-NO was shown to 
preferentially down-regulate cellular expression of the IAP family protein survivin, while 
little/no changes were detected in the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, 
or the pro-apoptotic protein Bax. Addition of the proteasome inhibitor lactacystin during PAPA-
NO treatment of tumor cells completely blocked accelerated survivin turnover, demonstrating the 
proteasome dependency of this process.  
The fact that PAPA-NO treatment selectively down-regulated survivin greatly encouraged 
me to further investigate whether there was any modulation in the sensitivity of treated tumor 
cells to apoptosis. When anti-Fas agonist Ab or FasL were used as apoptosis stimuli, we 
observed a markedly increased sensitivity of A20 cells to apoptosis. Given that the Fas-FasL 
pathway is essential to the effectiveness of DC-mediated A20 cell death, these data indirectly 
supported the hypothesis that such treatment would also sensitize A20 cells to DC-induced 
apoptosis. This was confirmed in the case of both immature and mature DCs. Of critical 
importance, this pre-conditioning regimen did not affect the sensitivity of normal B cells or B 
cell blasts to apoptotic stimuli, including DCs. These findings are important, since selective 
induction of tumor cell death without damaging normal tissue would be a major consideration for 
the ultimate translation of these findings into cancer immunotherapies.  
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 Similar to the wild-type (control) DCs, my data also suggest the involvement of FasL in the 
NO-induced tumor sensitization to DC-mediated killing. To confirm this, and at the same time 
demonstrate the role of any Fas-FasL independent pathway(s) in DC-mediated tumoricidal 
functions, we utilized DCs generated from FasL-deficient mice. As expected, the lack of FasL 
expression on DCs made them less efficient killers of A20 tumor cells, regardless of whether the 
tumor cells were pre-treated with PAPA-NO.  However, unlike wild-type DCs, where FasL 
played a dominant role in their killing activity, our data indicated that FasL was only partially 
involved in the ability of DCs to mediate cytotoxicity against NO-treated A20 cells. A more 
detailed study illustrated that TRAIL, and perhaps TNF-α, also actively participated in this 
process. In addition, these data indicated that NO pre-conditioning could sensitize A20 cells to 
the apoptosis induced by each of the FasL-Fas, TRAIL-TRAIL-R and TNF-α-TNFR pathways. 
Considering that these molecules play critical roles in the ability of both NK cells and CTLs to 
kill appropriate target cells, locoregional treatment of NO in vivo would be envisioned to 
sensitize tumor cells to not only DC, but NK- and CTL-mediated apoptosis as well.  Therefore 
this strategy would not only enhance antigen uptake and cross-presentation, resulting in 
improved effector cell priming/activation, but also directly improve the killing efficiency of 
effector NK cells and CTLs within the tumor microenvironment. Such expanded cytolytic 
activity could then promote additional rounds of cross-presentation of ApB-derived tumor 
antigens and enforce therapeutic anti-tumor immunity in situ. Overall, this would translate into 
more diversified and profound anti-tumor immune responses via the classical mechanism of 
“epitope spreading”. Moreover, due to their strong apoptosis-inducing capacity, the death 
receptor ligands FasL, TNF and TRAIL have been widely viewed as potential cancer therapy 
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 targets. If combined with a sensitization regimen, therapeutics targeting TNF family ligands 
might also result in improved treatment efficacy.  
Despite my intriguing preliminary findings, I have not formally provided the evidence 
supporting the direct correlation between NO-induced survivin down-regulation and tumor 
sensitization to apoptosis. The best way to do this is to examine whether tumor apoptosis could 
be augmented after survivin expression is specifically blocked in tumor cells.  In recent years 
many RNA-based silencing mechanisms have been reported. One of the most interesting 
discoveries was RNA interference (RNAi), a post-transcriptional sequence-specific gene-
silencing mechanism initiated by the introduction of double-stranded RNA (dsRNA) that are 
homologous in sequence to the silenced gene (215). Using small interference RNA (siRNA) 
specific to survivin, we were able to reduce the specific protein expression by approximately 
50% (Supplement figure 3A). A20 tumor cells that have been targeted with survivin siRNA 
exhibited increased apoptosis frequencies (Supplement figure 3B).  Although we could not 
exclude the possibility that other molecules might also be involved in NO-induced A20 
sensitization to apoptosis, I believe that survivin is a crucial contributing factor to this process. 
Even though I have now demonstrated a novel and potentially clinically-important effector 
function of DCs, their major role in adaptive immunity, undoubtedly, remains that of antigen-
presenting cells.  Based on my results generated during the course of this thesis research, a 
reasonable question to ask is whether the enhanced tumor sensitization to DC-mediated killing 
directly impacts ApB-derived antigen cross-presentation to specific T cells.  I approached this 
issue by choosing an OVA-expressing lymphoma cell line (EG7) as a primary tumor model.  As 
a byproduct of this experiment, I was able to generalize my initial conclusions that not only A20, 
but also other lymphoma cell lines (i.e. EL4, EG7) could be sensitized to DC-mediated apoptosis 
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 upon treatment with PAPA-NO, thereby expanding this type of intervention to multiple 
lymphomas at least.  
The usual way to test DC uptake of cellular antigens is to pre-label target cells with DiD 
(1,1'-dioctadecyl-3,3,3',3'-tetramethylindodi-carbocyanine perchlorate) or CFSE 
(carboxyfluorescein diacetate, succinimidyl ester or CFDA-SE) before co-incubating them with 
DCs. DC engulfment of antigen can then be examined by flow cytometry or via confocal 
fluorescence imaging. In our study evaluating the uptake of ApB by DC, these traditional dyes 
were inappropriate since DCs could also acquire membrane and intracellular protein antigens 
from live cells (212). The best surrogate index of apoptotic antigen uptake would be reflected in 
the acquisition of tumor cell nucleic acids, which would be released only upon tumor cell death. I 
selected the cell-permeant nucleic acid dye Hoechst 33342 to pre-label tumor cells due to its 
specificity and stability (i.e. lack of bleeding from pre-labeled cells). Using this dye, I 
demonstrated that DCs more readily acquired NO-sensitized vs. control, untreated tumor ApB in 
vitro. This could be clearly due to the increased tumor debris available to DCs after enhanced 
killing of tumor cells. While perhaps a subtlety, I remain unable to resolve whether the DC that 
mediates tumor apoptosis is the same cell that ultimately captures the ApB (i.e. antigen). 
Nonetheless, my interpretation of the available data is that DCs that kill tumor cells may 
themselves uptake some apoptotic antigens, and meanwhile, the amount of excess debris may 
recruit additional DCs as a “clean up” measure.   
One interesting finding of my studies is the impact of PTP inhibitors on tumor cell 
resistance to apoptosis. In my study, the accelerated turnover of anti-apoptotic protein survivin 
enhanced the sensitivity of tumor cells to DC-mediated apoptosis. Since NO-induced, 
proteasome-dependent degradation of alternative cellular proteins, including tumor-associated 
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 antigens, is expected, this treatment modality could also theoretically improve the processing and 
presentation of tumor epitopes to specific CD8+ T cells.  In addition to my findings implicating 
survivin as a conditional target in such a model, recent results from the Storkus lab also suggest 
that this may be the case for multiple tumor cells overexpressed receptor tyrosine kinases, such 
as EphA2 and EGFR. Hence, a careful selection of conditioning agents might positively and 
coordinately impact virtually all of the major events crucial to effective Type-1 anti-tumor 
immunity.   
As most immunotherapies would ultimately be translated through in vivo animal models, 
our laboratory now plans to apply this DC and sensitization regimen-combined therapy to tumor-
bearing mice. In this proposed study, in order to understand whether the cross-priming of T cells 
can be promoted, we will establish subcutaneous EG7 (H-2b) tumors in H-2b × H-2d F1 hybrid 
mice. Instead of using chemical agents such as NO donor compounds, we will be highly 
selective in injecting AdiNOS, an adenovirus encoding inversible NO synthesase gene, directly 
into tumor lesions. Cells infected by this virus will produce sustained levels of NO in situ, which 
will be expected to sensitize tumor cells to subsequently i.t. injected DCs. The efficacy of the 
sensitization regimen will be assessed by evaluating survivin expression in the treated tumor 
biopsies. Assuming survivin protein is reduced after AdiNOS injection, one day after virus 
administration, SM-DCs (H-2d) will be delivered intratumorally and CFSE labeled CD4+ T cells 
isolated from DO11.10/Rag2 KO (H-2d) mice will be adoptively-transferred into these recipient 
animals 48 hours later. CFSE is a cell-permeant fluorescein-related vital dye.  Because of its 
long-lived staining of intracellular proteins, flow cytometric analysis of lymphocyte proliferation 
can be achieved by determining serial halving of the fluorescence intensity of CFSE-labeled cells 
over time as daughter cells are generated (216). Since the tumor cells, transferred DCs and T 
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 cells are MHC mis-matched, labeled T cells could only be activated by H-2d DCs, which had 
acquired tumor ApB generated by injected H-2d DCs. Therefore, the activation of T cells will 
likely be the result of efficient cross-priming in situ. In addition, we will also monitor tumor 
growth every 2-3 days in order to determine whether there is any therapeutic benefit as a 
consequence of this therapy. If the therapy is successful, these data would provide confidence 
that intratumoral delivery of sensitizing agents and autologous DC in combinational therapies 
represent a viable treatment option for patients with cancer.  Studying the advance of such 
applications, however, has numerous considerations: i.e. what is the best and safest sensitization 
regimen to apply to humans? What is the proper dose and timing for such treatments? Which 
kind of tumors is most amenable to such treatments? When should DCs be injected after 
application of the sensitizing agent?  Should IL-12 and/or IL-18 cDNA engineered DCs be 
considered for injection in combined therapies given their enhanced efficacy noted in pre-clinical 
models?  Hence, while this thesis has generated at least as many questions as it has answered, 
there is great enthusiasm that effective combinational therapies can be designed based on 
optimizing DC-mediated killing and cross-presentation within the tumor microenvironment. 
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 Table 1. Cytokine Production from Control and Gene Engineered DCs. 
 
   Level of Cytokine Secreted*: 
DCs Evaluated   mIL-12   mIL-18 
Control DC (no Ad)  < .06   < .03 
Adψ5DC   < .06   < .03 
AdIL12DC   85.6 + 1.1  < .03 
AdIL18DC   0.86 + 0.03            6.3 + 0.2 
AdIL12/IL18DC  85.3 + 3.2            9.6 + 0.8 
 
* ng/5 x 106 DCs/48h.  Results are mean + SD of triplicate determinations and are representative of 3 
independent experiments performed. 
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 Table 2. Phenotypic Characteristics of Control and Gene Engineered DCs. 
 
 
    Mean Fluorescence Intensity (MFI)a 
DCs Evaluatedb MHC I  MHC II CD40 CD80 CD86 
Control DC (no Ad) 221 242 59 108   652 
Adψ5DC 214 244 64 103   644 
AdIL12.DC 317c 339c 51 106   685 
AdIL18DC 351c 349c 65 168c 1020c 
AdIL12/IL18DC 359c 414c 66   93   918c 
 
aValues represent the mean of MFI values obtained in 3 independent experiments. 
bDCs were harvested at day 7 of culture and either not infected or infected with the indicated adenoviral 
vectors.  Forty-eight hours later, DCs were recovered from culture and phenotyped for expression of the 
indicated markers. 
c p < 0.05 compared with mock-infected DCs.  
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Figure 1 The life cycle of dendritic cells (DC).  
 
Circulating precursor DCs enter tissues as immature DCs. They can also directly encounter 
pathogens (e.g. viruses) that induce secretion of cytokines (e.g. IFN ), which in turn can activate 
eosinophils, macrophages (MF), and natural killer (NK) cells. After antigen capture, immature 
DCs migrate to lymphoid organs where, after maturation, they display peptide-major 
histocompatibility complexes, which allow selection of rare circulating antigen-specific 
lymphocytes. These activated T cells help DCs in terminal maturation, which allows lymphocyte 
expansion and differentiation. Activated T lymphocytes migrate and can reach the injured tissue, 
because they can traverse inflamed epithelia. Helper T cells secrete cytokines, which permit 
activation of macrophages, NK cells, and eosinophils. Cytotoxic T cells eventually lyse the 
infected cells. B cells become activated after contact with T cells and DCs and then migrate into 
various areas where they mature into plasma cells, which produce antibodies that neutralize the 
initial pathogen. (Figure cited from Annu Rev Immunol. 2000;18:767-811) 
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Figure 2 Different antigen-processing pathways for the MHC class I and class II molecules. 
  a | MHC class I molecules present peptides that are primarily derived from endogenously 
synthesized proteins of either self or pathogen origin. These proteins are degraded into peptides 
by the proteasome and then transported through the transporters of antigen-processing (TAP) 
molecules into the endoplasmic reticulum for loading on MHC class I molecules. b | By contrast, 
MHC class II molecules present proteins that enter the cell through the endocytic route. During 
maturation of MHC class II molecules, they are prevented from binding to endogenous antigens 
in the endoplasmic reticulum by association with the invariant chain (Ii). Invariant chain–MHC 
class II complexes (MHC II–Ii) move through the Golgi to the MIIC/CIIV compartment where 
the invariant chain is degraded to CLIP (for class II-associated invariant-chain peptide). CLIP is 
then removed from the CLIP–MHC class II (MHC–CLIP) complexes and exchanged for 
antigenic peptide. c | Dendritic cells can endocytose antigens from other cells and cross-present 
them to CD8+ cytotoxic T lymphocytes. The TAP-dependence of such cross-presentation44, 52, 
indicates that it involves diversion of the cellular antigens into the conventional MHC class I 
pathway, although the mechanism(s) for this diversion are as yet undefined. In most cases, these 
antigens will also be processed into the MHC class II presentation pathway for recognition by 
CD4+ helper T cells. (MIIC, MHC II loading compartment; CIIV, MHC II vesicles.) (Figure 
cited from Nat Rev Immunol. 2001;1:126-135) 
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Figure 3 Apoptosis signalling through death receptors.   
Binding of death ligands (CD95L is used here as an example) to their receptor leads to the 
formation of the death-inducing signalling complex (DISC). In the DISC, the initiator 
procaspase-8 is recruited by FADD (FAS-associated death domain protein) and is activated by 
autocatalytic cleavage. Death-receptor-mediated apoptosis can be inhibited at several levels by 
anti-apoptotic proteins: CD95L can be prevented from binding to CD95 by soluble 'decoy' 
receptors, such as soluble CD95 (sCD95) or DcR3 (decoy receptor 3). FLICE-inhibitory proteins 
(FLIPs) bind to the DISC and prevent the activation of caspase-8; and inhibitors of apoptosis 
proteins (IAPs) bind to and inhibit caspases. FLIPL and FLIPS refer to long and short forms of 
FLIP, respectively. (Figure cited from Nat Rev Cancer. 2002;2:277-288) 
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Figure 4 Apoptosis signalling through mitochondria.   
 
Chemotherapy, irradiation and other stimuli can initiate apoptosis through the mitochondrial 
(intrinsic) pathway. Pro-apoptotic BCL2 family proteins — for example, BAX, BID, BAD and 
BIM — are important mediators of these signals. Activation of mitochondria leads to the release 
of cytochrome c (Cyt c) into the cytosol, where it binds apoptotic protease activating factor 1 
(APAF1) to form the apoptosome. At the apoptosome, the initiator caspase-9 is activated. 
Apoptosis through mitochondria can be inhibited on different levels by anti-apoptotic proteins, 
including the anti-apoptotic BCL2 family members BCL2 and BCL-XL and inhibitors of 
apoptosis proteins (IAPs), which are regulated by SMAC/DIABLO (second mitochondria-
derived activator of caspase/direct IAP binding protein with low pI). Another way is through 
survival signals, such as growth factors and cytokines, that activate the phosphatidylinositol 3-
kinase (PI3K) pathway. PI3K activates AKT, which phosphorylates and inactivates the pro-
apoptotic BCL2-family member BAD. (Figure cited from Nat Rev Cancer. 2002;2:277-288) 
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Figure 5 Expression of TNF family ligands on adenoviral trasnfected DCs.   
 
Bone marrow-derived DCs were infected with adenoviral vectors encoding mouse IL-12 
(AdIL12DC), mouse IL-18 (AdIL18DC), both AdIL12 and AdIL18 (AdIL12/IL18DC) or mock 
vector (Adψ5DC).  Adenoviral transduced or nontransduced DCs (DC) were stained with 
TRAIL, FasL or TNF-α specific antibodies, or isotype control antibodies and flow cytometry 
was performed.  Mean fluorescence intensities are indicated in each histogram panel. Similar 
results were obtained in three independent experiments. 
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Figure 6 Differential killing of CMS4 cells by adenovirally-infected DCs. 
 
(A) The tumoricidal activity of adenovirally infected DCs against CMS4 cancer cells was 
evaluated by using 24hr MTT assays.  The effector DCs and CMS4 target cells were mixed in a 
5:1 (DC:T) ratio and cytotoxicity assays were performed.  The percentages of specific killing are 
presented as box and whisker plots which display the median percent cytotoxicity (black bar) for 
each groups of adenovirally transfected DCs; the boxes show the interquartile range, the 
whiskers to 1.5 times the interquartile range. (B) For blocking of the interactions between the 
TNF family ligands and their receptors, adenovirally infected DCs (AdIL12/IL18DC) were 
preincubated for 60 minutes without antibody ((-)) or with antagonist antibodies against TRAIL 
(TRAIL), Fas ligand (FasL), TNF-α (TNF) or the combination of all three antibodies (triple).  
Box and whisker plots show the distribution of the percent cytotoxicity for each group. 
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Figure 7 Cytokine gene engineering of DCs promotes DC survival, tumor apoptosis and 
antigen uptake in situ. 
 
Day 7 BM-derived DCs were generated from BALB/c.EGFP mice and either not infected, or 
infected with the recombinant adenoviruses for 48h.  One million control or cytokine gene 
engineered DCs (or saline) were then injected into established day 7 CMS4 tumors.  After 24h, 
tumor lesions were resected, fixed, frozen, sectioned and stained for apoptotic cells using 
TUNEL.  Sections were also counterstained using Hoechst to detect nuclei. Panel A = Saline 
control; Panel B = Uninfected DCs, Panel C = Adψ5DC; Panel D = AdIL12DC; Panel E= 
AdIL18DC; Panel F = AdIL12/IL18DC.   Stained sections were then evaluated by flourescence 
microscopy at 20X magnification, with Panel C insert providing a 40X regional magnification 
and a 100X view of an EGFP+ DC containing an apoptotic (tumor) body. 
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Figure 8 Therapeutic effects of vaccination with IL-12 and/or IL-18 transduced DCs. 
 
Seven days after tumor inoculation, BALB/c mice bearing established CMS4 or MethA tumors 
were treated with the indicated intratumoral injection therapies (6 mice per treatment groups).  
(A) A mixed linear model was fit to the data and used to describe change in CMS4 tumor area 
over time. Each data point represents the least squares mean tumor size derived from the model 
along with the estimate of standard error.  (B) CMS4 tumor rejection rate expressed as 
percentage for the same mice shown in Figure 4A.  (C) Impact of intratumoral DC-based 
therapies on the growth of MethA tumors.  A mixed linear model was fit to the data and used to 
describe change in MethA tumor area over time.  Each data point represents the least squares 
mean tumor size derived from the model along with the estimate of standard error.  (D) Ab-
mediated in situ depletion of CD4+ or CD8+ T cells (as described in Materials and Methods) 
markedly reduces the therapeutic efficacy of AdIL12/IL18DC therapy.  Each data point 
represents the least squares mean tumor size derived from the model along with the estimate of 
standard error. 
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Figure 9 AdIL12/IL18DC-based therapy is superior to AdIL-12 + AdIL-18 intratumoral 
therapy. 
 
BALB/c mice bearing established day 7 CMS4 tumors were treated with intratumoral injections 
of either AdIL12/IL18DC or a mixture of the recombinant adenoviruses encoding IL-12 and IL-
18 (AdIL-12 and AdIL-18).  One week later, therapies were repeated.  Tumor size was 
monitored on the indicated days, with the reported values representing the mean tumor size ± 
standard error. Similar results were obtained in two independent experiments. 
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Figure 10 Specific IFNγ production from immune splenocytes. 
 
Mice bearing day 7 CMS4 tumors were treated with intratumoral injection of AdIL-12 and/or 
AdIL-18-infected DCs.  Splenocytes were harvested from mice 14 days after the last 
intratumoral injections (i.e. 28 days post-tumor inoculation), then cocultured with irradiated 
CMS4 cells for 5 days, prior to assessment of IFN-γ production from responder splenocytes 
against CMS4 target cells using specific ELISA assays.   Cytokine levels are reported in pg/ml 
(mean ±  SD of triplicate samples).  Similar results were obtained in two independent 
experiments. 
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Figure 11 Evaluation of the repertoire of natural CMS4-derived peptide epitopes 
recognized by CD8+ T cells in responder mice. 
 
Splenic CD8+ T cells were isolated from mice treated with adenovirally transfected DCs 
(AdIL12/IL18DC:IL-12 and IL-18 transduced DCs, AdIL18DC:IL-18 transduced DCs, 
AdIL12DC:IL-12 transduced DCs, AdΨ5DC:AdΨ5 transduced DCs, PBS: control).  Syngeneic 
DCs were pulsed with individual HPLC fractions containing resolved CMS4 peptides and used 
to stimulate CD8+ T cells for 48 hr, prior to harvesting culture supernatants for determination of 
IFN-γ concentrations measured by ELISA (in pg/ml; mean ± SD of triplicate samples). Similar 
results were obtained in two independent experiments. 
95 
  
 
Figure 12 Therapeutic effect of the AdIL12/IL18DC therapy on contralateral nontreated 
CMS4 tumors. 
 
Mice were first injected with 3x105 CMS4 cells in both flanks on day 0.  Seven days after tumor 
inoculation, BALB/c mice bearing established CMS4 tumors were treated in the right flank with 
the indicated intratumoral injection therapies as indicated in panel inserts (5 mice per treatment 
group).  Mean tumor area on each flank was determined for all mice bearing tumors (A: treated 
tumor growth, B: contralateral, non-treated tumor growth).  Each data point represents the mean 
tumor size ± standard error. The fraction of mice bearing a tumor in each treatment group at day 
28 is indicated in parentheses. AdIL12/IL18DC-treated tumors were significantly smaller in the 
injected tumor by day 10 and the non-injected tumor by day 14 (all p<0.01). 
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Figure 13 Phenotype of iDC and SM-DC.  
 
BM-derived DC were generated using a bulk-culture method (167). On day 7 and day 9, 
immature (iDC) and spontaneously-matured DC (SM-DC), respectively, were purified using 
CD11c MACS beads. DC were stained with specific Abs against (A) MHC class II and 
costimulatory molecules or (B) FasL, and flow cytometry performed. The results are presented 
as (A) overlays of single-color histograms obtained with isotype-matched control (open 
histograms) and specific Abs (filled histograms); and (B) single-color histograms. MFI are 
indicated in each histogram panel. These data are representative of three independent 
experiments performed. 
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Figure 14 SM-DC induce a greater degree of apoptosis in A20 B lymphoma cells than iDC. 
 
IDC and SM-DC were co-cultured with A20 tumor cells at a DC/T ratio of 2.5:1 or 5:1 for 4h. 
Cells were stained with PE-conjugated anti-B220 Abs and FITC-conjugated pan-caspase 
inhibitor z-VAD-FMK and analyzed by FACS. Tumor cell population was gated on B220 
positive staining. The percentage of cytotoxicity, indicated in the upper right quadrant, was 
calculated based on the fraction of apoptotic tumor cells (B220+VAD-FMK+) divided by total 
number of tumor cells (B220+). These data are representative of two independent experiments 
performed. 
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Figure 15 A20 cells are sensitive to Fas-mediated apoptosis. 
 
(A) A20 cells express membrane-bound Fas. Cell surface expression of Fas was assessed using a 
three-step flow cytometry technique, with the results depicted as overlays of isotype-matched 
control (open histogram) and Fas Ab (filled histograms) staining profiles. (B) Agonist anti-Fas 
Ab (Jo2) induces apoptosis in A20 tumor cells. A20 cells were incubated with anti-Fas Ab at the 
indicated concentrations for 24h at 37°C and cytotoxicity was evaluated by MTT assay. (C) 
Ligation of FasL by Fas triggers apoptosis in A20 cells. FasL-transfected (L5178Y.mFasL) or 
mock-transfected L5178Y cells (L5178Y) were co-incubated with A20 tumor cells at an E/T 
ratio of 5:1 for 4h. Cells were stained with a PE-labeled B220-specific mAb and FITC-labeled 
caspase activation marker z-VAD-FMK. DC cytotoxicity was calculated as described above. The 
results presented here are converted from density plots as shown in Figure 14. 
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Figure 16 DC-mediated A20 tumor ap
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(A) BM-derived DCs were generated fro
(gldDC). DC effector cells were then co-
5:1 for 4h. Cells were stained and analy
two independent experiments performed.
density plots into histogram. 
 
 
 
 optosis is mediated predominantly via the FasL-Fas 
m H-2d wild type (wtDC) or FasL-deficient gld mice 
incubated with A20 tumor cells at a DC/tumor ratio of 
zed as described above. The data are representative of 
 (B) The data shown in (A) have been converted from 
100 
                           
         
 
Figure 17 NO donor induced A20 cell apoptosis in a dose-dependent manner. 
 
A20 tumor cells were pre-incubated with PAPA-NO at the indicated concentrations for 1h at 
37°C. Control culture media were then replaced and the tumor cells maintained in culture 
overnight. Cells were then stained with VAD-FMK-FITC to detect apoptosis. These data are 
representative of two independent experiments performed. 
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Figure 18 A20 cells treated with low doses of PAPA-NO are sensitized to Fas-mediated 
apoptotic death. 
 
(A) NO-treated A20 cells were sensitized to anti-Fas Ab-induced apoptosis. Tumor cells were 
treated with PAPA-NO at the indicated concentrations for 1h at 37°C, and then incubated in 
fresh media in the presence or absence of anti-Fas Abs overnight. The MTT assay was used to 
determine cytotoxicity. These data are representative of three independent experiments 
performed. (B) NO-treated A20 cells were sensitized to FasL-mediated apoptosis. A20 cells were 
treated with NO donor as described in (A). 18h post treatment, FasL- or mock-transfected 
L5178Y cells were added to culture for 4h and cytotoxicity was evaluated as described above. 
These data are representative of two independent experiments performed. 
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Figure 19 NO pre-treatment significantly sensitizes A20 tumor cells to both iDC- and SM-
DC-mediated apoptosis. 
 
A20 cells were pre-treated with PAPA-NO as described in Figure 18 and then co-cultured with 
iDC (A) or SM-DC (B) for 4h in cytotoxicity assays. The statistical analyses of three 
independent experiments are provided in panel A. Panel B results are representative of 2 
independent experiments performed. 
103 
  
 
 
 
 
Figure 20 Pretreatment of PAPA-NO do not promote the apoptotic death of normal B cells. 
 
Bulk splenocytes were cultured at 37ºC in the presence of 10µg/ml LPS. Three days later, cells 
were harvested and treated with or without PAPA-NO at a final concentration of 25 µg/ml, 
before being co-cultured with SM-DCs as described above. Cells were gated on B220+ events 
and the data presented as overlays of histograms obtained with B cell only culture (open 
histograms) and B-DC co-culture (filled histograms). 
 
104 
  
 
 
Figure 21 Treatment of A20 tumor cells with PAPA-NO enhances their sensitivity to DC-
induced apoptosis through both Fas-dependent and -independent pathways. 
 
(A) A20 tumor cells were pretreated with PAPA-NO at the indicated concentrations before being 
co-incubated with DCs that were generated from either wild type mice (wtDC) or FasL-deficient 
mice (gldDC). DC cytotoxicity against tumor cells was analyzed as described in the Figrue 14 
legend. (B) DCs generated from the BM of FasL-deficient mice were cultured for 1h in the 
presence or absence of 20 µg/ml of anti-TNF Ab and/or anti-TRAIL Ab, or isotype control Ab. 
The DCs were then added to A20 cell cultures that has been pre-treated with 50 µg/ml of PAPA-
NO and analyzed for DC-mediated cytotoxicity as shown in (A). Data of density plots have been 
converted into histograms. 
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Figure 22 NO donor pre-treatment preferentially accelerates survivin protein turnover in 
A20 cells. 
 
(A) Whole cell lysates of PAPA-NO treated or untreated A20 tumor cells were prepared for 
Western blot analyses using anti-survivin, anti-Bcl-2, anti-Bcl-xL and anti-Bax Abs. (B) A20 
cells were treated with 300 µg/ml of PAPA-NO. Media were then changed and tumor cells 
maintained in CM in the presence or absence of 0.2 µM or 1 µM lactacystin (LC) for 4h. Whole 
cell lysates were prepared for immunoblot analyses using anti-survivin Ab, as described in the 
Materials and Methods. The results shown here have been normalized by expression of β-actin. 
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Figure 23 PAPA-NO pre-treatment enhances DC-mediated ApB uptake. 
 
(A) Pre-treatment of A20 tumor cells with PAPA-NO enhanced DC uptake of apoptotic tumor 
cells. A20 tumor cells were treated with 25 µg/ml of PAPA-NO as described above and stained 
with 4 µg/ml Hoechst 33342 for 30m. Cells were washed and maintained in culture for 
additional 3h before washing again and adding DCs at a DC/tumor ratio of 5 to 1. After 24h, the 
cells were harvested and stained with anti-mouse B220 mAb and PI, prior to flow cytometry 
analysis. Viable DCs (B220-PI-) were gated for analysis and MFI of Hoechst 33342 staining is 
reported. (B) Pre-treatment of EG7 (OVA+; H-2b) cells with PAPA-NO sensitized them to DC 
(H-2d)-mediated apoptosis. EG7 tumor cells were treated with 25 µg/ml PAPA-NO and 
coincubated with DCs, as described above. The cells were then stained with anti-mouse H-2Kd 
mAb and VAD-FMK-FITC to distinguish EG7 (Kd-neg) and DC (Kd+), and to determine 
viability, respectively, in the flow cytometry assays. (C) NO donor pre-treatment of EG7 cells 
increases uptake of tumor ApB by DCs. EG7 tumor cells were treated with PAPA-NO and 
stained with 1 µg/ml Hoechst 33342 before addition of DCs, as described in Material and 
Methods. Twenty-four hours later, cells were stained with anti-mouse H-2Kd mAb and PI. The 
DC populations were gated on H-2Kd and PI negative events and MFI of Hoechst 33342 staining 
was evaluated. 
107 
  
Figure 24 Pre-treatment with PAPA-NO enhances DC-mediated cross-presentation of 
OVA to tumor specific T cells. 
 
EL4 and EG7 tumor cells were pretreated with PAPA-NO at the indicated concentrations, prior 
to the addition of DCs. After 24h, 36h or 48h, DO11.10 T cell hybridoma was added to the 
culture and IL-2 production (per 106 DO11.10 cells) within 24h was tested by ELISA.  Positive 
controls included DC pulsed with the OVA323-339 peptide, with negative controls including DC 
pulsed with the MCS peptide and cohorts including the OVA-neg EL4 tumor cell line. Data are 
representative of two independent experiments performed. *p < 0.05 vs. corresponding data from 
untreated (i.e. NO 0 µg/ml) controls.   
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Figure 25. Further enrichment of CD11c+ DC over metrizamide gradients does not affect 
their capacity to mediate the apoptotic death of lymphoma cells in vitro. 
 
BM cells were cultured as described in our original Materials and Methods for 9 days. The cells 
were harvested and subjected to centrifugation on 14.5% (w/v) metrizamide gradients prior to 
CD11c MACS bead isolation.  CD11c+ purity of the Metrizamide + (MACS) Beads vs. Beads 
only preparations are depicted in the left panels of the figure.  Each population of DC was then 
used as effector cells against B220+ A20 cells (at a 5:1 DC-to-tumor cell ratio), with apoptosis 
monitored by flow cytometry as described in our Materials & Methods.  The DC populations 
mediated comparable levels of apoptotic killing of A20 cells. 
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Figure 26. Pretreatment with PAPA-NO enhances the sensitivity of EL4 cells to DC-
mediated apoptosis. 
 
EL4 tumor cells were pretreated with PAPA-NO at the indicated concentrations before being co-
incubated with SM-DCs. DC cytotoxicity against tumor cells was analyzed as described 
previously. The histogram shown here has been converted from density plots.  
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Figure 27. Inhibition of survivin expression in A20 cells using siRNA enhances their 
sensitivity to DC-mediated apoptosis. 
 
(A) Transfection of siRNA into A20 cells specifically reduced survivin expression by 50%. 
Negative control siRNA or siRNA (Ambion, Austin, TX) specific to murine survivin was 
transfected into A20 tumor cells at a final concertration of 100pmol using LipofectamineTM 2000 
following the manufacturer’s instruction. Twenty-four hours later, the same transfection 
procedure was repeated to enhance gene knockdown. After additional 24h culture at 37°C, cells 
were harvested and lysed for survivin expression analysis using Western blot. (B) Survivin-
siRNA transfection sensitized A20 tumor cells to DC-mediated apoptosis. A20 cells were 
transfected with siRNA as described in (A). Forty-eight hours after the first transfection, the cells 
were harvested and co-cultured with SM-DCs and 4h cytotoxicity assays were performed as 
described above. 
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